<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="tfap" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">tfap</book-part-id>
      <title-group>
        <title>Familial Transthyretin Amyloidosis</title>
        <alt-title alt-title-type="alt-title">Synonym: Familial TTR Amyloidosis</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sekijima</surname>
            <given-names>Yoshiki</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>sekijima@shinshu-u.ac.jp</email>
          <aff>Division of Clinical and Molecular Genetics <break/>Shinshu University Hospital<break/>Matsumoto, Japan</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yoshida</surname>
            <given-names>Kunihiro</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>kyoshida@shinshu-u.ac.jp</email>
          <aff>Department of Medicine (Neurology &#x00026; Rheumatology)<break/>Shinshu University Hospital <break/>Matsumoto, Japan</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tokuda</surname>
            <given-names>Takahiko</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>ttokuda@koto.kpu-m.ac.jp</email>
          <aff>Department of Neurology<break/>Kyoto Prefectural University Hospital<break/>Kyoto, Japan</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ikeda</surname>
            <given-names>Shu-ichi</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>ikedasi@shinshu-u.ac.jp</email>
          <aff>Department of Medicine (Neurology &#x00026; Rheumatology)<break/>Shinshu University Hospital <break/>Matsumoto, Japan</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2001-11-05" date-type="created">
          <day>5</day>
          <month>11</month>
          <year>2001</year>
        </date>
        <date iso-8601-date="2012-01-26" date-type="updated">
          <day>26</day>
          <month>1</month>
          <year>2012</year>
        </date>
        <date iso-8601-date="2005-03-02" date-type="revised">
          <day>2</day>
          <month>3</month>
          <year>2005</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="porphyria-ct" document-type="chapter">Familial Porphyria Cutanea Tarda</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="fa" document-type="chapter">Fanconi Anemia</related-object>
      <abstract id="tfap.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Familial transthyretin (TTR) amyloidosis is characterized by a slowly progressive peripheral sensorimotor neuropathy and autonomic neuropathy as well as non-neuropathic changes of cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis. The disease usually begins in the third to fifth decade in persons from endemic foci in Portugal and Japan; onset is later in persons from other areas. Typically, sensory neuropathy starts in the lower extremities with paresthesias and hypesthesias of the feet, followed within a few years by motor neuropathy. In some persons, particularly those with early onset disease, autonomic neuropathy is the first manifestation of the condition; findings can include: orthostatic hypotension, constipation alternating with diarrhea, attacks of nausea and vomiting, delayed gastric emptying, sexual impotence, anhidrosis, and urinary retention or incontinence. Cardiac amyloidosis is mainly characterized by progressive cardiomyopathy. Individuals with leptomeningeal amyloidosis may have the following CNS findings: dementia, psychosis, visual impairment, headache, seizures, motor paresis, ataxia, myelopathy, hydrocephalus, or intracranial hemorrhage.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>In addition to clinical symptoms, proven amyloid deposition in biopsy specimens and identification of a pathogenic variant in <italic toggle="yes">TTR</italic> are necessary to establish the diagnosis. TTR amyloid deposition in tissue is demonstrated using Congo red staining and, ideally, immunohistochemical study. Although mass spectrometry can demonstrate a mass difference between wild-type and TTR protein variants in serum, it does not specify the site and kind of amino acid substitution in a number of disease-related <italic toggle="yes">TTR</italic> variants; thus, DNA sequencing is usually required. Sequence analysis of <italic toggle="yes">TTR</italic>, the only gene in which mutation is known to cause TTR amyloidosis, detects more than 99% of pathogenic variants.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Orthotopic liver transplantation (OTLX) halts the progression of peripheral and/or autonomic neuropathy; OTLX is recommended in individuals younger than age 60 years with: (1) disease duration less than five years, (2) polyneuropathy restricted to the lower extremities or with autonomic neuropathy alone, and (3) no significant cardiac or renal dysfunction. Surgery is indicated for carpal tunnel syndrome and vitrectomy for vitreous involvement. In those with sick sinus syndrome or second-degree or third-degree AV block, a cardiac pacemaker may be indicated.</p>
          <p><italic toggle="yes">Surveillance:</italic> Serial nerve conduction studies to monitor polyneuropathy; serial electrocardiogram, echocardiography, and serum B-type natriuretic peptide (BNP) level to monitor cardiomyopathy; modified body mass index (mBMI) to monitor nutritional status.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Local heating appliances, such as hot-water bottles, which can cause low-temperature burn injury in those with decreased temperature and pain perception.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the family-specific pathogenic variant is known, molecular genetic testing ensures early diagnosis and treatment. If the familial variant is not known, clinical evaluations ensure early diagnosis and treatment.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Familial TTR amyloidosis is inherited in an autosomal dominant manner. Each child of an affected individual (who is heterozygous for one <italic toggle="yes">TTR</italic> pathogenic variant) has a 50% chance of inheriting the <italic toggle="yes">TTR</italic> variant. For affected individuals homozygous for <italic toggle="yes">TTR</italic> pathogenic variants:</p>
          <list list-type="bullet">
            <list-item>
              <p>Each sib is at a 50% risk of inheriting one <italic toggle="yes">TTR</italic> pathogenic variant and a 25% risk of inheriting two <italic toggle="yes">TTR</italic> pathogenic variants;</p>
            </list-item>
            <list-item>
              <p>All offspring will inherit a pathogenic variant.</p>
            </list-item>
          </list>
          <p>Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant has been identified in the family. Requests for prenatal testing for adult-onset conditions which (like familial TTR amyloidosis) do not affect intellect and have some treatment available are not common.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="tfap.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="tfap.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_tfap.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Familial Transthyretin Amyloidosis: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_tfap.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Familial amyloid polyneuropathy type I (Portuguese-Swedish-Japanese type)</p>
                    </list-item>
                    <list-item>
                      <p>Familial amyloid polyneuropathy type II (Indiana/Swiss or Maryland/German type)</p>
                    </list-item>
                    <list-item>
                      <p>Familial amyloid cardiomyopathy</p>
                    </list-item>
                    <list-item>
                      <p>Leptomeningeal amyloidosis</p>
                    </list-item>
                    <list-item>
                      <p>Familial oculoleptomeningeal amyloidosis (FOLMA)</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="tfap.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="tfap.Diagnosis">
        <title>Diagnosis</title>
        <sec id="tfap.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of familial transthyretin (TTR) amyloidosis is suspected in adults with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Slowly progressive sensorimotor and/or autonomic neuropathy that is frequently accompanied by one or more of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Cardiac conduction blocks</p>
                </list-item>
                <list-item>
                  <p>Cardiomyopathy</p>
                </list-item>
                <list-item>
                  <p>Nephropathy</p>
                </list-item>
                <list-item>
                  <p>Vitreous opacities</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Family history consistent with autosomal dominant inheritance supports the diagnosis; however, absence of other affected individuals in the family does not preclude the diagnosis of familial TTR amyloidosis especially in persons older than age 50 years.</p>
            </list-item>
          </list>
        </sec>
        <sec id="tfap.Testing">
          <title>Testing</title>
          <p><bold>Tissue biopsy.</bold> To confirm amyloidosis, including familial TTR amyloidosis, the demonstration of amyloid deposition on biopsied tissues is essential. Deposition of amyloid in tissue can be demonstrated by Congo red staining of biopsy materials. With Congo red staining, amyloid deposits show a characteristic yellow-green birefringence under polarized light. Tissues suitable for biopsy include: subcutaneous fatty tissue of the abdominal wall, skin, gastric or rectal mucosa, sural nerve, and peritendinous fat from specimens obtained at carpal tunnel surgery. Sensitivity of endoscopic biopsy of gastrointestinal mucosa is around 85%; biopsy of the sural nerve is less sensitive because amyloid deposition is often patchy [<xref ref-type="bibr" rid="tfap.REF.hund.2001.431">Hund et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.koike.2004.129">Koike et al 2004</xref>, <xref ref-type="bibr" rid="tfap.REF.vital.2004.232">Vital et al 2004</xref>].</p>
          <p>It is ideal to show that these amyloid deposits are specifically immunolabeled by anti-TTR antibodies.</p>
          <p><bold>Serum variant TTR protein.</bold> TTR protein normally circulates in serum or plasma as a soluble protein having a tetrameric structure [<xref ref-type="bibr" rid="tfap.REF.kelly.1998.101">Kelly 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.rochet.2000.60">Rochet &#x00026; Lansbury 2000</xref>]. Normal plasma TTR concentration is 20-40 mg/dL (0.20-0.40 mg/mL).</p>
          <p>Pathogenic variants in <italic toggle="yes">TTR</italic> cause conformational change in the TTR protein molecule, disrupting the stability of the TTR tetramer, which is then more easily dissociated into pro-amyloidogenic monomers [<xref ref-type="bibr" rid="tfap.REF.sekijima.2005.73">Sekijima et al 2005</xref>]. Small amounts of TTR monomer (0.28-0.56 &#x000b5;g/mL) can be detected in the plasma of individuals with familial TTR amyloidosis and normal controls [<xref ref-type="bibr" rid="tfap.REF.sekijima.2001.257">Sekijima et al 2001</xref>].</p>
          <p>After immunoprecipitation with anti-TTR antibody, serum variant TTR protein can be detected by mass spectrometry [<xref ref-type="bibr" rid="tfap.REF.tachibana.1999.282">Tachibana et al 1999</xref>]. Approximately 90% of TTR variants so far identified are confirmed by this method. Mass shift associated with each variant TTR protein is indicated [<xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>].</p>
          <sec id="tfap.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">TTR</italic> is the only gene in which mutation is known to cause familial TTR amyloidosis.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="tfap.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Familial Transthyretin Amyloidosis</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">TTR</italic>
                    </td>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted mutation analysis</td>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">c.148G&#x0003e;A</xref> (<xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Val30Met</xref>)&#x000a0;<sup>4,&#x000a0;5</sup></td>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">100% of the targeted variant</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;99%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions</td>
                    <td headers="hd_h_tfap.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown; none reported</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="tfap.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="tfap" object-id="tfap.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="tfap.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="tfap.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="tfap.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a pathogenic variant that is present in the indicated gene</p>
                </fn>
                <fn id="tfap.TF.1.4">
                  <label>4. </label>
                  <p>Identified in many individuals of different ethnic backgrounds; found in large clusters in Portugal, Sweden, and Japan</p>
                </fn>
                <fn id="tfap.TF.1.5">
                  <label>5. </label>
                  <p>Targeted mutation panel may vary by laboratory.</p>
                </fn>
                <fn id="tfap.TF.1.6">
                  <label>6. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="tfap.TF.1.7">
                  <label>7. </label>
                  <p>The gene has four exons; and all the hitherto-identified pathogenic variants are in exons 2, 3, or 4.</p>
                </fn>
                <fn id="tfap.TF.1.8">
                  <label>8. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="tfap.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Tissue biopsy to document the presence of amyloid using Congo red staining and immunohistohemical study with anti-TTR antibodies</p>
            </list-item>
            <list-item>
              <p>Note: Mass spectrometry to detect serum TTR protein variants may also be useful for screening.</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing of <italic toggle="yes">TTR</italic> by sequence analysis (may be preceded by targeted mutation analysis)</p>
            </list-item>
            <list-item>
              <p>Deletion/duplication testing:</p>
              <list list-type="bullet">
                <list-item>
                  <p>No exon or whole-gene deletions or duplications involving <italic toggle="yes">TTR</italic> have been reported to cause familial transthyretin amyloidosis.</p>
                </list-item>
                <list-item>
                  <p>However, with new deletion/duplication testing methods, it is theoretically possible that such variants may be identified in affected individuals in whom prior testing by sequence analysis of the entire coding region was negative.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior identification of the pathogenic variant in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="tfap.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="tfap.Clinical_Description">
          <title>Clinical Description</title>
          <p>Clinical features of familial transthyretin (TTR) amyloidosis can include peripheral sensorimotor neuropathy and autonomic neuropathy, as well as non-neuropathic changes (cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis) (see <xref ref-type="table" rid="tfap.T.phenotypes_associated_with_famili">Table 2</xref>).</p>
          <table-wrap id="tfap.T.phenotypes_associated_with_famili" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Phenotypes Associated with Familial Transthyretin Amyloidosis</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Phenotype</th>
                  <th id="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_2">Representative Genotype</th>
                </tr>
                <tr>
                  <th headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1" id="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type</th>
                  <th headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1" id="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Features</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">TTR amyloid neuropathy <break/>(formerly familial amyloid polyneuropathy type I [Portuguese-Swedish-Japanese type])</td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Early:
<list list-type="bullet"><list-item><p>Sensorimotor polyneuropathy of the legs</p></list-item><list-item><p>Carpal tunnel syndrome</p></list-item><list-item><p>Autonomic dysfunction</p></list-item><list-item><p>Constipation/ diarrhea</p></list-item><list-item><p>Impotence</p></list-item></list>
Late:
<list list-type="bullet"><list-item><p>Cardiomyopathy</p></list-item><list-item><p>Vitreous opacities</p></list-item><list-item><p>Nephropathy</p></list-item></list></td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Val30Met</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">TTR amyloid neuropathy <break/>(formerly familial amyloid polyneuropathy type II [Indiana/Swiss; Maryland/German type])</td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Early:
<list list-type="bullet"><list-item><p>Carpal tunnel syndrome</p></list-item></list>
Late:
<list list-type="bullet"><list-item><p>Sensorimotor polyneuropathy of extremities</p></list-item><list-item><p>Autonomic dysfunction</p></list-item><list-item><p>Constipation / diarrhea</p></list-item><list-item><p>Impotence</p></list-item><list-item><p>Cardiomyopathy</p></list-item><list-item><p>Vitreous opacities</p></list-item><list-item><p>Nephropathy</p></list-item></list></td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Ile84Ser</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">TTR cardiac amyloidosis<break/>(familial amyloid cardiomyopathy)</td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Cardiomegaly</p>
                      </list-item>
                      <list-item>
                        <p>Conduction block</p>
                      </list-item>
                      <list-item>
                        <p>Arrhythmia</p>
                      </list-item>
                      <list-item>
                        <p>Anginal pain</p>
                      </list-item>
                      <list-item>
                        <p>Congestive heart failure</p>
                      </list-item>
                      <list-item>
                        <p>Sudden death</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Val122Ile</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">TTR leptomeningeal/<break/>CNS amyloidosis</td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_1 hd_h_tfap.T.phenotypes_associated_with_famili_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Dementia</p>
                      </list-item>
                      <list-item>
                        <p>Ataxia</p>
                      </list-item>
                      <list-item>
                        <p>Spasticity</p>
                      </list-item>
                      <list-item>
                        <p>Seizures</p>
                      </list-item>
                      <list-item>
                        <p>Hemorrhage (intracerebral and/or subarachnoid)</p>
                      </list-item>
                      <list-item>
                        <p>Psychosis</p>
                      </list-item>
                      <list-item>
                        <p>Hydrocephalus</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_tfap.T.phenotypes_associated_with_famili_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Asp18Gly</xref>
                  </td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p><bold>Neuropathy.</bold> The cardinal feature of TTR-familial amyloid polyneuropathy type I is slowly progressive sensorimotor and autonomic neuropathy [<xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.hund.2001.431">Hund et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.ando.2005.1057">Ando et al 2005</xref>]. Typically, sensory neuropathy starts in the lower extremities and is followed by motor neuropathy within a few years. The initial signs of this sensory neuropathy are paresthesias (sense of burning, shooting pain) and hypesthesias of the feet. Temperature and pain sensation are impaired earlier than vibration and position sensation. By the time sensory neuropathy progresses to the level of the knees, the hands have usually become affected. In the full-blown stage of the disease, sensory loss, muscle atrophy, and weakness of the extremities show a glove and stocking distribution. Foot drop, wrist drop, and disability of the hands and fingers are common symptoms of motor neuropathy.</p>
          <p>Autonomic neuropathy may occur as the first clinical symptom of the disease (<xref ref-type="table" rid="tfap.T.symptoms_at_presentation_of_famil">Table 3</xref>). The symptoms of autonomic dysfunction include: orthostatic hypotension [<xref ref-type="bibr" rid="tfap.REF.vita.2005.259">Vita et al 2005</xref>], constipation alternating with diarrhea, attacks of nausea and vomiting, delayed gastric emptying, sexual impotence, anhidrosis, and urinary retention or incontinence. Because of sensory loss and autonomic dysfunction, trophic ulcers on the lower extremities are common. Frequently, the autonomic neuropathy produces the most significant morbidity of the disorder.</p>
          <table-wrap id="tfap.T.symptoms_at_presentation_of_famil" position="anchor" orientation="portrait">
            <label>Table 3. </label>
            <caption>
              <p>Symptoms at Presentation of Familial Amyloid Polyneuropathy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" rowspan="2" valign="middle" colspan="2" align="left" scope="colgroup" headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1">Symptoms</th>
                  <th id="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">% of Individuals</th>
                </tr>
                <tr>
                  <th headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2" id="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">From <xref ref-type="bibr" rid="tfap.REF.coelho.1994.293">Coelho et al [1994]</xref></th>
                  <th headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2" id="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">From <xref ref-type="bibr" rid="tfap.REF.ikeda.1987.315">Ikeda et al [1987]</xref></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Sensory <break/>(lower limbs)</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Most commonly paresthesias</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">80%</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">49%</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" rowspan="6" valign="middle" align="left" scope="row" colspan="1">Autonomic</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Vomiting</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">3%</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Constipation</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">21%</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">18%</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Constipation alternating with diarrhea</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">12%</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">---</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Diarrhea</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">17%</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">4%</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Impotence</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">24%</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">9%</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Orthostatic fainting</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">---</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">7%</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Motor</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Weakness</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">7%</td>
                  <td headers="hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_1_2 hd_h_tfap.T.symptoms_at_presentation_of_famil_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">7%</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p>The disease usually begins in the third, fourth, or fifth decade in persons from endemic foci in Portugal and Japan; onset is later in persons from other areas. The following findings indicate that age at onset varies greatly even within ethnically identical populations with the same <italic toggle="yes">TTR</italic> pathogenic variant:</p>
          <list list-type="bullet">
            <list-item>
              <p>For persons of Japanese ancestry with the <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Val30Met</xref> variant who are related to two large endemic foci (Ogawa village and Arao city), the mean age at onset is 40.1&#x000b1;12.8 years (range 22-74 years) [<xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>].</p>
            </list-item>
            <list-item>
              <p>For persons of Japanese ancestry with Val30Met who are unrelated to two large endemic foci, the mean age at onset is much later (62.7&#x000b1;6.6 years) (range 52-80 years) [<xref ref-type="bibr" rid="tfap.REF.misu.1999.1951">Misu et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.ikeda.2002.1001">Ikeda et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>For persons of Portuguese ancestry with the Val30Met variant, the mean age at onset is 33.5 &#x000b1;9.4 years (range 17-78 years).</p>
            </list-item>
            <list-item>
              <p>For persons of Swedish, French, or British ancestry, the mean age at onset is much later than that in individuals of Japanese or Portuguese ancestry [<xref ref-type="bibr" rid="tfap.REF.plant_bordeneuve.1998.708">Plant&#x000e9;-Bordeneuve et al 1998</xref>].</p>
            </list-item>
          </list>
          <p>Sensorimotor neuropathy and autonomic neuropathy progress over ten to 20 years. Various types of cardiac conduction block frequently appear. Cachexia is a common feature at the late stage of the disease. Affected individuals usually die of cardiac failure, renal failure, or infection.</p>
          <p>TTR-familial amyloid polyneuropathy type II (or the Indiana/Swiss or Maryland/German type) starts in the upper extremities as carpal tunnel syndrome in association with specific <italic toggle="yes">TTR</italic> variants (e.g., Leu58His, Leu58Arg, Lys70Asn, Ile84Ser, Tyr114His (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2000.54">Connors et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.hund.2001.431">Hund et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>]. Sensorimotor neuropathy and autonomic neuropathy are accompanied by visceral involvement. Cardiomyopathy and/or nephropathy are frequently seen in the advanced stage of the disease.</p>
          <p><bold>Non-neuropathic amyloidosis.</bold> Individuals with familial TTR amyloidosis do not necessarily present with polyneuropathy. Cardiac amyloidosis and leptomeningeal amyloidosis are well-known non-neuropathic forms of familial TTR amyloidosis that are associated with specific <italic toggle="yes">TTR</italic> variants. In these types of familial TTR amyloidosis, polyneuropathy is absent or, if present, less evident.</p>
          <p>Approximately one third of the TTR protein variants are accompanied by vitreous opacities.</p>
          <p><bold>Cardiac amyloidosis.</bold> Cardiac amyloidosis, mainly characterized by progressive cardiomyopathy, has been associated with more than two thirds of <italic toggle="yes">TTR</italic> pathogenic variants (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2001.493">Saraiva 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.hattori.2003.229">Hattori et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</xref>]. In some families with specific <italic toggle="yes">TTR</italic> variants, such as Asp18Asn, Val20Ile, Pro24Ser, Ala45Thr, Ala45Ser, His56Arg, Gly57Arg, Ile68Leu, Ala81Thr, Ala81Val, His88Arg, Glu92Lys, Arg103Ser, Leu111Met, or Val122Ile (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>), cardiomyopathy without peripheral neuropathy is a main feature of the disease.</p>
          <p>Cardiac amyloidosis is usually late onset. Most individuals develop cardiac symptoms after age 50 years; cardiac amyloidosis generally presents with restrictive cardiomyopathy. The typical electrocardiogram shows a pseudoinfarction pattern with prominent Q wave in leads II, III, <sub>a</sub>V<sub>F</sub>, and V<sub>1</sub>-V<sub>3</sub>, presumably resulting from dense amyloid deposition in the anterobasal or anteroseptal wall of the left ventricle. The echocardiogram reveals left ventricular hypertrophy with preserved systolic function. The thickened walls present "a granular sparkling appearance."</p>
          <p>Among the variants responsible for cardiac amyloidosis, <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Val122Ile</xref> is notable for its prevalence in African Americans. Approximately 3.0%-3.9% of African Americans are heterozygous for Val122Ile [<xref ref-type="bibr" rid="tfap.REF.yamashita.2005.127">Yamashita et al 2005</xref>]. The high frequency of Val122Ile partly explains the observation that in individuals in the US older than age 60 years, cardiac amyloidosis is four times more common among blacks than whites [<xref ref-type="bibr" rid="tfap.REF.jacobson.1997.466">Jacobson et al 1997</xref>].</p>
          <p><bold>Leptomeningeal (oculoleptomeningeal) amyloidosis.</bold> Amyloid deposition is seen in the pial and arachnoid membrane, as well as in the walls of vessels in the subarachnoid space associated with <italic toggle="yes">TTR</italic> pathogenic variants including Leu12Pro, Asp18Gly, Ala25Thr, Val30Gly, Ala36Pro, Gly53Glu, Gly53Ala, Phe64Ser, Tyr69His, or Tyr114Cys (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.petersen.1997.307">Petersen et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.brett.1999.183">Brett et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.mascalchi.1999.1498">Mascalchi et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.uemichi.1999.1152">Uemichi et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2000.54">Connors et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.ellie.2001.135">Ellie et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2001.493">Saraiva 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.ikeda.2002.1001">Ikeda et al 2002</xref>, <xref ref-type="bibr" rid="tfap.REF.blevins.2003.1625">Blevins et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.hammarstr_m.2003.6656">Hammarstr&#x000f6;m et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2003.409">Sekijima et al 2003</xref>]. Amyloid in the blood vessels disappears as the vessels penetrate the brain parenchyma.</p>
          <p>Individuals with leptomeningeal amyloidosis show CNS signs and symptoms including: dementia, psychosis, visual impairment, headache, seizures, motor paresis, ataxia, myelopathy, hydrocephalus, or intracranial hemorrhage.</p>
          <p>When associated with vitreous amyloid deposits, leptomeningeal amyloidosis is known as <italic toggle="yes">f</italic>amilial <italic toggle="yes">o</italic>culo<italic toggle="yes">l</italic>epto<italic toggle="yes">m</italic>eningeal <italic toggle="yes">a</italic>myloidosis (FOLMA) [<xref ref-type="bibr" rid="tfap.REF.petersen.1997.307">Petersen et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.jin.2004.1463">Jin et al 2004</xref>].</p>
          <p>In leptomeningeal amyloidosis protein concentration in the cerebrospinal fluid is usually high, and gadolinium-enhanced MRI typically shows extensive enhancement of the surface of the brain, ventricles, and spinal cord [<xref ref-type="bibr" rid="tfap.REF.brett.1999.183">Brett et al 1999</xref>].</p>
          <p>Although meningeal biopsy is necessary to confirm amyloid deposition in the meninges, characteristic MRI findings and the presence of a pathogenic variant in <italic toggle="yes">TTR</italic> strongly suggest this pathology [<xref ref-type="bibr" rid="tfap.REF.mitsuhashi.2004.265">Mitsuhashi et al 2004</xref>].</p>
          <p><bold>Other.</bold> Vitreous opacification has been reported in approximately 20% of families with various <italic toggle="yes">TTR</italic> pathogenic variants, including <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Val30Met</xref> [<xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.kawaji.2004.257">Kawaji et al 2004</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</xref>]. Four out of 43 individuals with the Val30Met variant developed vitreous amyloidosis as the first manifestation of familial TTR amyloidosis [<xref ref-type="bibr" rid="tfap.REF.kawaji.2004.257">Kawaji et al 2004</xref>]. In one case report, vitreous opacification was the only evidence of amyloid deposit caused by the <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Trp41Leu</xref> variant [<xref ref-type="bibr" rid="tfap.REF.yazaki.2002.263">Yazaki et al 2002</xref>].</p>
          <p>The kidney is consistently involved with marked deposition of amyloid demonstrated at postmortem examination. Mild to severe renal involvement is usually seen in the advanced stage [<xref ref-type="bibr" rid="tfap.REF.haagsma.2004.44">Haagsma et al 2004</xref>, <xref ref-type="bibr" rid="tfap.REF.lobato.2004.27">Lobato et al 2004</xref>].</p>
          <p>Amyloid deposition on the gastrointestinal tract wall, especially with involvement of the gastrointestinal autonomic nerves, is common [<xref ref-type="bibr" rid="tfap.REF.ikeda.1982.1364">Ikeda et al 1982</xref>, <xref ref-type="bibr" rid="tfap.REF.ikeda.1983.1055">Ikeda et al 1983</xref>].</p>
          <p>Nodular cutaneous amyloidosis has been reported in an individual with the <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Thr114His</xref> variant [<xref ref-type="bibr" rid="tfap.REF.mochizuki.2001.105">Mochizuki et al 2001</xref>].</p>
          <p>Shortness of breath induced by diffuse pulmonary amyloid deposition has been reported in two individuals with the <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Asp38Ala</xref> variant [<xref ref-type="bibr" rid="tfap.REF.yazak.2000">Yazak et al 2000</xref>].</p>
          <p>Anemia with low erythropoietin has been reported in 25% of cases [<xref ref-type="bibr" rid="tfap.REF.beir_o.2004.2004">Beir&#x000e3;o et al 2004</xref>].</p>
        </sec>
        <sec id="tfap.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p><bold>Heterozygotes.</bold> With expanding lists of pathogenic variants in <italic toggle="yes">TTR</italic> (<xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>), genotype-phenotype correlations have been intensively investigated; however, they remain largely undetected.</p>
          <p>In subsets of families with the <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Val30Met</xref> variant, considerable variation in phenotypic manifestations and age of onset is observed. It is hypothesized that genetic modifiers and non-genetic factors contribute to the pathogenesis and progression of familial TTR amyloidosis [<xref ref-type="bibr" rid="tfap.REF.holmgren.1997.178">Holmgren et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.misu.1999.1951">Misu et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.munarqu_s.1999.629">Munar-Qu&#x000e9;s et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.sobue.2003.32">Sobue et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.soares.2005.543">Soares et al 2005</xref>].</p>
          <p>It has been clinically and experimentally demonstrated that the benign allelic variant <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">c.416C&#x0003e;T</xref> (Thr119Met) has a protective effect on amyloidogenesis in individuals who have the Val30Met variant [<xref ref-type="bibr" rid="tfap.REF.longo_alves.1997.662">Longo Alves et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.hammarstr_m.2001.2459">Hammarstr&#x000f6;m et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.sebasti_o.2001.733">Sebasti&#x000e3;o et al 2001</xref>].</p>
          <p>Most of the more than 90 pathogenic variants in <italic toggle="yes">TTR</italic> result in classic peripheral and autonomic neuropathy; but some variants are considered to be associated with unique phenotypes of familial TTR amyloidosis, in which peripheral or autonomic neuropathy is clinically absent or less prominent:</p>
          <list list-type="bullet">
            <list-item>
              <p>Cardiac amyloidosis is caused by Asp18Asn, Val20Ile, Pro24Ser, Ala45Thr, Ala45Ser, His56Arg, Gly57Arg, Ile68Leu, Ala81Thr, Ala81Val, His88Arg, Glu92Lys, Arg103Ser, Leu111Met, or Val122Ile (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2001.493">Saraiva 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</xref>]. Peripheral and autonomic neuropathy are absent or less evident in persons with these variants.</p>
            </list-item>
            <list-item>
              <p>Leptomeningeal amyloidosis is associated with Leu12Pro, Asp18Gly, Ala25Thr, Val30Gly, Ala36Pro, Gly53Glu, Gly53Ala, Phe64Ser, Tyr69His, or Tyr114Cys (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.petersen.1997.307">Petersen et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.brett.1999.183">Brett et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.mascalchi.1999.1498">Mascalchi et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.uemichi.1999.1152">Uemichi et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2000.54">Connors et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.ellie.2001.135">Ellie et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2001.493">Saraiva 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.ikeda.2002.1001">Ikeda et al 2002</xref>, <xref ref-type="bibr" rid="tfap.REF.blevins.2003.1625">Blevins et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.hammarstr_m.2003.6656">Hammarstr&#x000f6;m et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2003.409">Sekijima et al 2003</xref>]. It has been demonstrated that highly destabilized <italic toggle="yes">TTR</italic> variants induce leptomeningeal amyloidosis [<xref ref-type="bibr" rid="tfap.REF.hammarstr_m.2001.2459">Hammarstr&#x000f6;m et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2003.409">Sekijima et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2005.73">Sekijima et al 2005</xref>].</p>
            </list-item>
          </list>
          <p><bold>Homozygotes</bold>. The vast majority of individuals with familial TTR amyloidosis are heterozygous for a <italic toggle="yes">TTR</italic> pathogenic variant; however, homozygotes have been reported:</p>
          <list list-type="bullet">
            <list-item>
              <p>At least 19 homozygotes for Val30Met from 14 families [<xref ref-type="bibr" rid="tfap.REF.munarqu_s.2001.121">Munar-Qu&#x000e9;s et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.tojo.2008.796">Tojo et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p>Eight homozygotes for variants other than Val30Met: Val122Ile (5), Leu58His (1), Phe64Leu (1), and Ile68Leu (1) (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.jacobson.1990.127">Jacobson et al 1990</xref>, <xref ref-type="bibr" rid="tfap.REF.nichols.1991.175">Nichols et al 1991</xref>, <xref ref-type="bibr" rid="tfap.REF.ferlini.1996.10">Ferlini et al 1996</xref>, <xref ref-type="bibr" rid="tfap.REF.askanas.2000.544">Askanas et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.jacob.2007.127">Jacob et al 2007</xref>, <xref ref-type="bibr" rid="tfap.REF.perfetto.2011.450">Perfetto et al 2011</xref>]</p>
            </list-item>
          </list>
          <p>Homozygotes present with a slightly more severe clinical course (higher incidence rate and earlier onset) than heterozygotes within the same family [<xref ref-type="bibr" rid="tfap.REF.tojo.2008.796">Tojo et al 2008</xref>]; amyloid deposition is more widespread in homozygotes than in heterozygotes [<xref ref-type="bibr" rid="tfap.REF.yoshinaga.2004.56">Yoshinaga et al 2004</xref>]. Most homozygotes are members of families characterized by incomplete penetrance of familial TTR amyloidosis.</p>
        </sec>
        <sec id="tfap.Penetrance">
          <title>Penetrance</title>
          <p>Because the penetrance for familial TTR amyloidosis is not 100%, an individual with a <italic toggle="yes">TTR</italic> pathogenic variant may be symptom free until late adulthood. The penetrance may vary by variant, geographic region, or ethnic group.</p>
          <p>It is generally accepted that the penetrance is much higher in individuals in endemic foci than outside of endemic foci [<xref ref-type="bibr" rid="tfap.REF.misu.1999.1951">Misu et al 1999</xref>]. In Portugal, cumulative disease risk in individuals with the Val30Met variant is estimated at 80% by age 50 and 91% by age 70 years, whereas the risk in French heterozygotes is 14% by age 50 and 50% by age 70 years [<xref ref-type="bibr" rid="tfap.REF.plant_bordeneuve.2003.e120">Plant&#x000e9;-Bordeneuve et al 2003</xref>]. In Sweden, the penetrance is much lower: 1.7% by age 30, 5% by age 40, 11% by age 50, 22% by age 60, 36% by age 70, 52% by age 80, and 69% by age 90, respectively [<xref ref-type="bibr" rid="tfap.REF.hellman.2008.181">Hellman et al 2008</xref>].</p>
          <p>Some Val30Met homozygotes remain asymptomatic.</p>
        </sec>
        <sec id="tfap.Anticipation">
          <title>Anticipation</title>
          <p>Genetic anticipation is observed in families with TTR amyloid polyneuropathy from endemic areas [<xref ref-type="bibr" rid="tfap.REF.yamamoto.1998.23">Yamamoto et al 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.soares.1999.480">Soares et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.misu.2000.451">Misu et al 2000</xref>]. In Japanese families with the Val30Met pathogenic variant, which originated from one of two endemic foci, it was reported that affected children with maternal transmission showed more profound anticipation than those with paternal transmission, especially when the children were male [<xref ref-type="bibr" rid="tfap.REF.yamamoto.1998.23">Yamamoto et al 1998</xref>].</p>
          <p>However, because not all asymptomatic individuals in these studies underwent molecular genetic testing, some asymptomatic individuals with the Val30Met variant may not have been identified, in which case the occurrence of anticipation would be overestimated. Furthermore, male gender is known to be a genetic risk factor for TTR amyloidosis [<xref ref-type="bibr" rid="tfap.REF.misu.1999.1951">Misu et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.koike.2002.1771">Koike et al 2002</xref>, <xref ref-type="bibr" rid="tfap.REF.hellman.2008.181">Hellman et al 2008</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2011.1785">Sekijima et al 2011</xref>], which may explain why affected male children developed TTR amyloidosis at an earlier age than their mothers.</p>
        </sec>
        <sec id="tfap.Nomenclature">
          <title>Nomenclature</title>
          <p>The neuropathy associated with <italic toggle="yes">TTR</italic> pathogenic variants, now called familial TTR amyloidosis, was formerly referred to as one of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Familial amyloid polyneuropathy type I (or the Portuguese-Swedish-Japanese type)</p>
            </list-item>
            <list-item>
              <p>Familial amyloid polyneuropathy type II (or the Indiana/Swiss or Maryland/German type)</p>
            </list-item>
          </list>
        </sec>
        <sec id="tfap.Prevalence">
          <title>Prevalence</title>
          <p>The Val30Met pathogenic variant, found worldwide, is the most widely studied <italic toggle="yes">TTR</italic> variant and is responsible for the well-known large foci of individuals with TTR amyloid polyneuropathy in Portugal, Sweden, and Japan. Numerous families with various pathogenic variants other than Val30Met have also been identified worldwide (<xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>).</p>
          <p>The frequency of familial TTR amyloidosis caused by the variant Val30Met is estimated to be one in 538 in northern Portugal (Povoa do Varzim and Vila do Conde), the largest cluster worldwide of individuals with familial TTR amyloidosis.</p>
          <p>In individuals of northern European origin in the US, the frequency of Val30Met-related familial TTR amyloidosis is estimated to be one in 100,000 [<xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>].</p>
          <p>The frequency of Val30Met heterozygotes is 1.5% in the northern part of Sweden [<xref ref-type="bibr" rid="tfap.REF.holmgren.1994.351">Holmgren et al 1994</xref>]; however, the penetrance is very low in this area [<xref ref-type="bibr" rid="tfap.REF.hellman.2008.181">Hellman et al 2008</xref>] (see <xref ref-type="sec" rid="tfap.Penetrance">Penetrance</xref>).</p>
          <p>The frequency of Val122Ile in the African American population is 3.0%-3.9%; most heterozygous individuals develop late-onset cardiac amyloidosis. More than 5% of the population in some areas of West Africa is heterozygous for this variant. In the US, the frequency of Val122Ile in the white and Hispanic populations is 0.44% and 0.0%, respectively [<xref ref-type="bibr" rid="tfap.REF.jacobson.1997.466">Jacobson et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.yamashita.2005.127">Yamashita et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="tfap.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold>Familial euthyroid hyperthyroxinemia</bold> is caused by benign allelic variants in <italic toggle="yes">TTR</italic>, including Gly6Ser, Ala109Thr, Ala109Val, and Thr119Met (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2001.493">Saraiva 2001</xref>]. The TTR protein binds approximately 15% of serum thyroxine. These variants increase total serum thyroxine concentration because of their increased affinity for thyroxine, however, they increase neither free thyroxine nor free triiodothyronine. Therefore, individuals with these sequence variants develop no clinical symptoms (i.e., they are euthyroid).</p>
        <p><bold>Senile systemic amyloidosis</bold> (SSA; previously called senile cardiac amyloidosis) results from the pathologic deposition of wild-type TTR, predominantly in the heart. Pathologic deposits are also seen in the lungs, blood vessels, and the renal medulla of the kidneys [<xref ref-type="bibr" rid="tfap.REF.westermark.2003.48">Westermark et al 2003</xref>]. SSA affects mainly the elderly but is rarely diagnosed during life. Thus, the precise prevalence of SSA is still unknown, but the examination of autopsy samples revealed a prevalence of 10%-25% in the elderly (age &#x0003e;80 years).</p>
        <p>SSA is typically asymptomatic or manifest by cardiac symptoms. Some individuals with SSA present with carpal tunnel syndrome. SSA should be distinguished from familial TTR amyloidosis with variant TTR or other forms of amyloidosis such as primary (AL) amyloidosis. In contrast to the rapid progression of heart failure in AL amyloidosis, SSA results in slowly progressive heart failure [<xref ref-type="bibr" rid="tfap.REF.ng.2005.1425">Ng et al 2005</xref>]. <xref ref-type="bibr" rid="tfap.REF.westermark.2003.48">Westermark et al [2003]</xref> have indicated that the lung may be a more reliable tissue for amyloid detection than the heart.</p>
      </sec>
      <sec id="tfap.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>A total of 20 amyloidogenic proteins including transthyretin (TTR) have been identified in human amyloidoses [<xref ref-type="bibr" rid="tfap.REF.buxbaum.2000.543">Buxbaum &#x00026; Tagoe 2000</xref>]. Among the hereditary amyloidoses, familial TTR amyloidosis is the most prevalent. Other hereditary amyloidoses are summarized in <xref ref-type="table" rid="tfap.T.other_hereditary_amyloidoses">Table 4</xref> [<xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.hund.2001.431">Hund et al 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2005.75">Benson 2005</xref>].</p>
        <table-wrap id="tfap.T.other_hereditary_amyloidoses" position="anchor" orientation="portrait">
          <label>Table 4. </label>
          <caption>
            <p>Other Hereditary Amyloidoses</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type</th>
                <th id="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Disease Name</th>
                <th id="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Phenotype</th>
                <th id="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Neuropathic</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Apo AI amyloidosis (formerly familial amyloid polyneuropathy-III [Iowa type])</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Early:
<list list-type="bullet"><list-item><p>Nephropathy</p></list-item><list-item><p>Gastric ulcers</p></list-item><list-item><p>Polyneuropathy</p></list-item></list></td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Apolipoprotein A-I</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gelsolin amyloidosis (formerly familial amyloid polyneuropathy-IV [Finnish-Danish type])</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Cranial neuropathy</p>
                    </list-item>
                    <list-item>
                      <p>Corneal lattice dystrophy</p>
                    </list-item>
                    <list-item>
                      <p>Polyneuropathy</p>
                    </list-item>
                    <list-item>
                      <p>Carpal tunnel syndrome</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Gelsolin</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">Non-neuropathic</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Fibrinogen A &#x003b1;-associated amyloidosis</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Nephropathy</p>
                    </list-item>
                    <list-item>
                      <p>Petechiae</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Fibrinogen A &#x003b1;</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Lysozyme-associated amyloidosis</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Nephropathy</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Lysozyme</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="fmf" document-type="chapter">Familial Mediterranean fever</related-object>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Nephropathy</p>
                    </list-item>
                    <list-item>
                      <p>Peritonitis</p>
                    </list-item>
                    <list-item>
                      <p>Periodic fever</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Pyrin (marenostrin)</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Apo AII amyloidosis</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Nephropathy</p>
                    </list-item>
                    <list-item>
                      <p>Gastrointestinal hemorrhage</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Apolipoprotein A-II</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_1" rowspan="7" valign="middle" align="left" scope="row" colspan="1">Cerebral</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="alzheimer-early" document-type="chapter">Alzheimer disease type 3</related-object>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Dementia</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Presenilin 1</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="alzheimer-early" document-type="chapter">Alzheimer disease type 4</related-object>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" colspan="1" align="left" rowspan="1">Presenilin 2</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1"><related-object link-type="booklink" source-id="gene" document-id="alzheimer-early" document-type="chapter">Alzheimer disease type 1</related-object> (Swedish, London, Florida, Flemish, Arctic, Iowa type)</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" colspan="1" align="left" rowspan="1">Amyloid precursor protein</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Hereditary cerebral hemorrhage with amyloid (Dutch type)</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Cerebral hemorrhage</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Amyloid precursor protein</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Cystatin C amyloidosis (Icelandic type)</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Cerebral hemorrhage</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Cystatin C</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Familial British dementia</td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Dementia</p>
                    </list-item>
                    <list-item>
                      <p>Ataxia</p>
                    </list-item>
                    <list-item>
                      <p>Spastic palsy</p>
                    </list-item>
                    <list-item>
                      <p>Cataract</p>
                    </list-item>
                    <list-item>
                      <p>Hearing loss</p>
                    </list-item>
                  </list>
                </td>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_4" rowspan="2" valign="middle" align="left" colspan="1">BRI</td>
              </tr>
              <tr>
                <td headers="hd_h_tfap.T.other_hereditary_amyloidoses_1_1_1_2" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Familial Danish dementia</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Non-hereditary systemic amyloidoses include senile systemic amyloidosis (SSA), immunoglobulin (AL) amyloidosis, reactive (secondary, AA) amyloidosis, and &#x000df;2-microglobulin (dialysis-associated) amyloidosis. Approximately one third of individuals with AL amyloidosis have neuropathic symptoms such as polyneuropathy, autonomic neuropathy,or carpal tunnel syndrome. Therefore, it is sometimes difficult to clinically distinguish familial TTR amyloidosis from AL amyloidosis. Immunohistochemical study of biopsied tissue is necessary for the diagnosis of both types of amyloidosis.</p>
        <p>Other acquired and familial causes of neuropathy need to be considered (see <related-object link-type="booklink" source-id="gene" document-id="cmt" document-type="chapter">Charcot-Marie-Tooth Hereditary Neuropathy Overview</related-object>). Non-hereditary, non-amyloidotic causes of neuropathy such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Crow-Fukase syndrome (also known as POEMS [<italic toggle="yes">p</italic>lasma cell neoplasia with <italic toggle="yes">p</italic>olyneuropathy, <italic toggle="yes">o</italic>rganomegaly, <italic toggle="yes">e</italic>ndocrinopathy, <italic toggle="yes">M</italic> protein, and <italic toggle="yes">s</italic>kin changes]), diabetic neuropathy, or Shy-Drager syndrome should be considered, particularly when family history is negative and when the disease is in the early stage. CIDP is the most common diagnostic error; 18/90 patients with familial TTR amyloidosis without a family history were mistakenly diagnosed with CIDP [<xref ref-type="bibr" rid="tfap.REF.plant_bordeneuve.2007.693">Plant&#x000e9;-Bordeneuve et al 2007</xref>].</p>
        <p>If cardiomyopathy or CNS manifestations (rather than sensorimotor or autonomic neuropathy) are prominent, a wide variety of diseases should be considered. Cardiac amyloidosis should be differentiated from <related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis</related-object>, glycogen storage diseases (e.g., <related-object link-type="booklink" source-id="gene" document-id="gsd2" document-type="chapter">Pompe disease</related-object>), <related-object link-type="booklink" source-id="gene" document-id="fabry" document-type="chapter">Fabry disease</related-object>, cardiac sarcoidosis, and mitochondrial cytopathy (<related-object link-type="booklink" source-id="gene" document-id="melas" document-type="chapter">MELAS</related-object>), all of which may present with restrictive cardiomyopathy.</p>
      </sec>
      <sec id="tfap.Management_1">
        <title>Management</title>
        <sec id="tfap.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with familial transthyretin (TTR) amyloidosis, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete neurologic assessment including baseline nerve conduction studies</p>
            </list-item>
            <list-item>
              <p>Evaluation of the heart:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Echocardiogram, the most useful noninvasive test for cardiac amyloidosis, for visualization of ventricular wall thickness, ventricular septal thickness, and hyperrefractile myocardial echoes (so called "granular sparkling appearance")</p>
                </list-item>
                <list-item>
                  <p>Electrocardiogram (ECG) to evaluate for characteristic findings of cardiac amyloidosis including low voltage in the standard limb leads and QS pattern in the right precordial leads with or without conduction blocks</p>
                </list-item>
                <list-item>
                  <p>Myocardial technetium-99m-pyrophosphate scintigraphy to visualize amyloid deposition in heart [<xref ref-type="bibr" rid="tfap.REF.ikeda.2004.1107">Ikeda 2004</xref>]</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Gadolinium-enhanced MRI of the brain and spinal cord to evaluate CNS amyloidosis [<xref ref-type="bibr" rid="tfap.REF.mitsuhashi.2004.265">Mitsuhashi et al 2004</xref>]</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation</p>
            </list-item>
            <list-item>
              <p>Evaluation of renal function</p>
            </list-item>
            <list-item>
              <p>Genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="tfap.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Carpal tunnel release surgery for carpal tunnel syndrome</p>
            </list-item>
            <list-item>
              <p>Vitrectomy for vitreous involvement</p>
            </list-item>
            <list-item>
              <p>Cardiac pacemaker implantation for second-degree or third-degree AV block and sick sinus syndrome.</p>
            </list-item>
          </list>
        </sec>
        <sec id="tfap.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p><bold>Orthotopic liver transplantation (OLTX).</bold> The only effective therapy for the neuropathy of familial TTR amyloidosis is orthotopic liver transplantation (OLTX), which removes the main production site of the amyloidogenic protein. Successful OLTX results in rapid disappearance of variant TTR protein from the serum and thus halts the progression of peripheral and/or autonomic neuropathy. It has been shown by pre- and postoperative sural nerve biopsy that myelinated nerve fibers regenerate after OLTX [<xref ref-type="bibr" rid="tfap.REF.ikeda.1997.618">Ikeda et al 1997</xref>].</p>
          <p><bold>Recommended clinical criteria for OLTX</bold> in individuals with TTR amyloid polyneuropathy [<xref ref-type="bibr" rid="tfap.REF.takei.1999.592">Takei et al 1999</xref>, <xref ref-type="bibr" rid="tfap.REF.adams.2000.1495">Adams et al 2000</xref>] include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Age younger than 60 years</p>
            </list-item>
            <list-item>
              <p>Disease duration less than five years</p>
            </list-item>
            <list-item>
              <p>Either polyneuropathy that is restricted to the lower extremities or autonomic neuropathy alone</p>
            </list-item>
            <list-item>
              <p>No significant cardiac or renal dysfunction</p>
            </list-item>
          </list>
          <p>As of the end of June 2010, 1913 individuals with familial TTR amyloidosis, approximately 90% of whom were heterozygous for the Val30Met variant, had undergone liver transplantation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fapwtr.org/ram_fap.htm">www.fapwtr.org/ram_fap.htm</ext-link>) [<xref ref-type="bibr" rid="tfap.REF.ericzon.2000.145">Ericzon et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.ikeda.2003.547">Ikeda et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.herlenius.2004.64">Herlenius et al 2004</xref>, <xref ref-type="bibr" rid="tfap.REF.stangou.2004.615">Stangou &#x00026; Hawkins 2004</xref>]. The five-year survival rate was significantly higher in individuals with the Val30Met variant than in those with other pathogenic variants (80% vs 57%, p=0.001) [<xref ref-type="bibr" rid="tfap.REF.ericzon.2000.145">Ericzon et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.ikeda.2003.547">Ikeda et al 2003</xref>]. The most common causes of postoperative death were cardiovascular events (29%) and septicemia (26%) [<xref ref-type="bibr" rid="tfap.REF.ikeda.2003.547">Ikeda et al 2003</xref>].</p>
          <p><bold>Poor outcomes of transplanted individuals</bold> based on ten years' experience [<xref ref-type="bibr" rid="tfap.REF.ikeda.2003.547">Ikeda et al 2003</xref>] include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Poor nutritional condition (mean body mass index &#x0003c;600)</p>
            </list-item>
            <list-item>
              <p>Severe polyneuropathy (Norris score &#x0003c;55/81)</p>
            </list-item>
            <list-item>
              <p>Permanent urinary incontinence</p>
            </list-item>
            <list-item>
              <p>Marked postural hypotension</p>
            </list-item>
            <list-item>
              <p>A fixed pulse rate</p>
            </list-item>
          </list>
          <p><bold>OLTX is not effective</bold> in the non-neuropathic forms of familial TTR amyloidosis (i.e., cardiac amyloidosis, leptomeningeal amyloidosis, and familial oculoleptomeningeal amyloidosis [FOLMA]).</p>
          <p>Cardiomyopathy was reported to progress after OLTX in some individuals with specific pathogenic variants other than Val30Met (Ala36Pro, Glu42Gly, and Ser77Tyr) (see <xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.dubrey.1997.74">Dubrey et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.stangou.1998.229">Stangou et al 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.yazaki.2000.702">Yazaki et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.h_rnsten.2004.112">H&#x000f6;rnsten et al 2004</xref>]. It is presumed that amyloid cardiomyopathy may accelerate after OLTX by progressive deposition of wild-type TTR on a template of amyloid derived from variant TTR [<xref ref-type="bibr" rid="tfap.REF.yazaki.2000.702">Yazaki et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.h_rnsten.2004.112">H&#x000f6;rnsten et al 2004</xref>]. Therefore, it is critical to assess the severity of cardiac amyloidosis when considering OLTX [<xref ref-type="bibr" rid="tfap.REF.coutinho.2004.201">Coutinho et al 2004</xref>, <xref ref-type="bibr" rid="tfap.REF.juneblad.2004.208">Juneblad et al 2004</xref>].</p>
          <p>Individuals with leptomeningeal involvement may not be candidates for liver transplantation because amyloidogenic TTR variants that cause intracranial amyloid deposits are considered to be derived from the choroid plexus.</p>
          <p>Vitreous opacities may also progress after OLTX, possibly as the result of <italic toggle="yes">de novo</italic> production of variant TTR in the retinal epithelium.</p>
          <p>Note: Because liver involvement in familial TTR amyloidosis is minimal, the liver of an individual with familial TTR amyloidosis can be grafted into an individual with liver cancer or end-stage liver disease (so-called "domino" liver transplantation). Since 1995, more than 330 domino liver transplantations have been performed. Several individuals who had received a liver graft from heterozygotes with familial TTR amyloidosis developed symptomatic systemic TTR amyloidosis [<xref ref-type="bibr" rid="tfap.REF.stangou.2005.2356">Stangou et al 2005</xref>, <xref ref-type="bibr" rid="tfap.REF.goto.2006.2512">Goto et al 2006</xref>, <xref ref-type="bibr" rid="tfap.REF.barreiros.2010.109">Barreiros et al 2010</xref>, <xref ref-type="bibr" rid="tfap.REF.llad_.2010.1386">Llad&#x000f3; et al 2010</xref>, <xref ref-type="bibr" rid="tfap.REF.obayashi.2011.449">Obayashi et al 2011</xref>, <xref ref-type="bibr" rid="tfap.REF.adams.2011.174">Adams et al 2011</xref>]</p>
        </sec>
        <sec id="tfap.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Cardiac pacing for persons with familial TTR amyloidosis with conduction block helps prevent sudden death.</p>
        </sec>
        <sec id="tfap.Surveillance">
          <title>Surveillance</title>
          <p>Serial nerve conduction studies can be used to objectively monitor the course of the polyneuropathy.</p>
          <p>Serial electrocardiogram, echocardiography, and serum B-type natriuretic peptide (BNP) level can be used to monitor the course of cardiomyopathy and conduction block.</p>
          <p>Modified body mass index (mBMI) can be used to monitor nutritional status.</p>
        </sec>
        <sec id="tfap.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Since most individuals with familial TTR amyloidosis have decreased temperature and pain perception, affected individuals should not use local heating appliances, such as hot-water bottles, which can cause low-temperature burn injury.</p>
        </sec>
        <sec id="tfap.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>If the pathogenic variant has been identified in an affected family member, it is appropriate to offer molecular genetic testing to at-risk relatives so that morbidity and mortality can be reduced by early diagnosis and treatment.</p>
          <p>If the pathogenic variant in the family is not known, it is appropriate to offer clinical diagnostic evaluations to identify those family members who will benefit from early treatment.</p>
          <p>See <xref ref-type="sec" rid="tfap.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="tfap.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Strategies of potential molecular therapies for familial TTR amyloidosis include the following [<xref ref-type="bibr" rid="tfap.REF.saraiva.2002.1">Saraiva 2002</xref>, <xref ref-type="bibr" rid="tfap.REF.ando.2003.55">Ando 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2008.3219">Sekijima et al 2008</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Inhibition of synthesis of variant TTR</p>
            </list-item>
            <list-item>
              <p>Stabilization of variant TTR</p>
            </list-item>
            <list-item>
              <p>Inhibition of aggregation of amyloidogenic intermediates</p>
            </list-item>
            <list-item>
              <p>Disruption of insoluble amyloid fibrils</p>
            </list-item>
          </list>
          <p>Drugs that stabilize the TTR tetramer and prevent dissociation into monomers and drugs that disrupt TTR amyloid fibrils into amorphous materials have been designed [<xref ref-type="bibr" rid="tfap.REF.saraiva.2002.1">Saraiva 2002</xref>, <xref ref-type="bibr" rid="tfap.REF.miller.2004.545">Miller et al 2004</xref>, <xref ref-type="bibr" rid="tfap.REF.almeida.2005.641">Almeida et al 2005</xref>].</p>
          <p>Phase I and II clinical trials of diflunisal showed that diflunisal increased serum TTR stability in persons with familial TTR amyloidosis beyond the level of normal controls without adverse effects. A randomized double-blind placebo-controlled multicenter/multinational clinical trial is currently underway to determine whether diflunisal will alter the progression of familial TTR amyloidosis [<xref ref-type="bibr" rid="tfap.REF.sekijima.2006.236">Sekijima et al 2006</xref>, <xref ref-type="bibr" rid="tfap.REF.tojo.2006.441">Tojo et al 2006</xref>]. This study is currently fully enrolled; results are anticipated in December, 2012.</p>
          <p>Recently, tafamidis(Vyndaqel<sup>&#x000ae;</sup>), a small molecule that binds TTR tetramer selectively and potently, has been developed as a TTR kinetic stabilizer to ameliorate familial TTR amyloidosis. In a dose escalation Phase I study in healthy volunteers, tafamidis was found to be safe and well tolerated. In addition, tafamidis showed strong TTR stabilization effects in plasma of study participants. Phase II/III studies of tafamidis showed efficacy in delaying peripheral neurologic impairment compared with individuals treated with placebo. In addition, tafamidis resulted in improved nutritional status (modified body mass index, mBMI) of the study participants.</p>
          <p>Based on these findings, the European Commission approved tafamidis for the treatment of familial TTR amyloid polyneuropathy in adult individuals with stage 1 symptomatic polyneuropathy in November 2011. Tafamidis will be available by prescription in Europe in early 2012.</p>
          <p>Inhibition of variant TTR mRNA expression by small interfering RNAs (siRNA) [<xref ref-type="bibr" rid="tfap.REF.love.2010.1864">Love et al 2010</xref>] and antisense oligonucleotide [<xref ref-type="bibr" rid="tfap.REF.benson.2006.609">Benson et al 2006</xref>] is also under investigation.</p>
          <p>In July 2010, Alnylam pharmaceuticals initiated dosing in a Phase I human clinical study with siRNA. The Phase I study was designed as a randomized, placebo-controlled, single-dose escalation study in individuals with familial TTR amyloidosis. The administration of siRNA(ALN-TTR01) resulted in statistically significant reductions in serum TTR protein levels in affected individuals. Lowering of serum TTR protein was found to be dose dependent, rapid, and durable after just a single dose.</p>
          <p>Isis pharmaceuticals is currently evaluating oligonucleotide targeting of TTR amyloidosis (ISIS-TTRRx) in a Phase I study.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="tfap.Other">
          <title>Other</title>
          <p>Plasma exchange, affinity column binding with a monoclonal antibody, and use of a special column with affinity for TTR were considered as possible methods for elimination of amyloidogenic TTR from the blood circulation. Serum TTR levels decreased significantly immediately after treatment, but then returned to the same levels as before treatment because of the rapid turnover of TTR. Therefore, these methods were concluded not to be effective for familial TTR amyloidosis.</p>
          <p>4&#x02019;-iodo-4&#x02019;-deoxydoxorubicin (IDOX) has been reported to bind to several types of amyloid and lead to the catabolism of amyloid in deposits. In a multicenter clinical trial, IDOX was administered to persons with AL amyloidosis; however, no obvious benefit could be detected.</p>
        </sec>
      </sec>
      <sec id="tfap.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="tfap.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Familial transthyretin (TTR) amyloidosis is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="tfap.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Some individuals diagnosed with familial TTR amyloidosis have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with familial TTR amyloidosis may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include molecular genetic testing if the pathogenic variant in <italic toggle="yes">TTR</italic> has been identified in the proband.Note: The family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs depends on the genetic status of the parents.</p>
            </list-item>
            <list-item>
              <p>Sibs of an affected individual have a 50% chance of inheriting a <italic toggle="yes">TTR</italic> pathogenic variant if one parent has a pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>At least 26 homozygous persons with familial TTR amyloidosis have been reported. In this circumstance, sibs of the proband have a 50% chance of inheriting one <italic toggle="yes">TTR</italic> pathogenic variant and a 25% chance of inheriting two <italic toggle="yes">TTR</italic> pathogenic variants.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the DNA of either parent, the risk to sibs is low but greater than that of the general population because (although no instances have been reported to date) germline mosaicism remains a possibility.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Every child of an affected individual has a 50% risk of inheriting a pathogenic variant in <italic toggle="yes">TTR</italic>.</p>
            </list-item>
            <list-item>
              <p>If the proband is homozygous for a <italic toggle="yes">TTR</italic> pathogenic variant, all offspring will inherit the variant.</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the genetic status of the proband's parents. If a parent is affected or has a pathogenic variant, his or her family members are at risk.</p>
        </sec>
        <sec id="tfap.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="tfap.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p><bold>Testing of at-risk asymptomatic adults.</bold> Testing of at-risk asymptomatic adults for familial TTR amyloidosis is possible using the techniques described in <xref ref-type="sec" rid="tfap.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>. Such testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. When testing at-risk individuals for familial TTR amyloidosis, an affected family member should be tested first to confirm the molecular diagnosis in the family.</p>
          <p>Testing for the pathogenic variant in the absence of definite symptoms of the disease is predictive testing. At-risk symptomatic adult family members may seek testing in order to make personal decisions regarding reproduction, financial matters, and career planning. Others may have different motivations including simply the "need to know." Testing of asymptomatic at-risk adult family members usually involves pretest interviews in which the motives for requesting the test, the individual's knowledge of familial TTR amyloidosis, the possible impact of positive and negative test results, and neurologic status are assessed. Those seeking testing should be counseled regarding possible problems that they may encounter with regard to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Other issues to consider are implications for the at-risk status of other family members. Informed consent should be procured and records kept confidential. Individuals with a positive test result need arrangements for long-term follow-up and evaluation.</p>
          <p><bold>Related liver transplantation donors.</bold> In Japan, where liver transplantation from living, related donors is the generally accepted therapy of familial TTR amyloidosis, molecular genetic testing of asymptomatic adult relatives is always performed on family members volunteering to be donors.</p>
          <p><bold>Molecular genetic testing of asymptomatic individuals younger than age 18 years</bold> who are at risk for adult-onset disorders is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p>
          <p>Children who are symptomatic usually benefit from having a specific diagnosis established. See also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals</p>
        </sec>
        <sec id="tfap.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variant has been identified in the family, prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks&#x02019; gestation) or chorionic villus sampling (usually performed at ~10-12 weeks&#x02019; gestation).</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p>Requests for prenatal testing for adult-onset conditions which (like familial TTR amyloidosis) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD</bold>) has been reported [<xref ref-type="bibr" rid="tfap.REF.almeida.2005.641">Almeida et al 2005</xref>] and may be an option for some families in which the pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="tfap.Resources">
        <title>Resources</title>
      </sec>
      <sec id="tfap.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="tfap.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The main component of amyloid is protein fibrils. In familial transthyretin (TTR) amyloidosis, the fibrils are mainly composed of self-aggregated TTR protein. TTR protein is potentially amyloidogenic because of its extensive beta-sheet structure. The key factor in amyloidogenesis in familial TTR amyloidosis is the stability of the TTR protein [<xref ref-type="bibr" rid="tfap.REF.kelly.1998.101">Kelly 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.rochet.2000.60">Rochet &#x00026; Lansbury 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2005.73">Sekijima et al 2005</xref>]. The TTR protein normally circulates in plasma as a soluble protein having a tetrameric structure. The amyloidogenic process is understood to comprise two steps: soluble TTR tetramers dissociate into pro-amyloidogenic monomers that, in turn, polymerize into amyloid fibrils in certain tissues [<xref ref-type="bibr" rid="tfap.REF.kelly.1998.101">Kelly 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.rochet.2000.60">Rochet &#x00026; Lansbury 2000</xref>]. Pathogenic variants in <italic toggle="yes">TTR</italic> cause significant conformational change in TTR protein molecules, in turn disrupting the stability of the TTR tetramer. In other words, a tetramer containing variant TTR monomers is more easily dissociated into pro-amyloidogenic monomers than is a normal TTR tetramer [<xref ref-type="bibr" rid="tfap.REF.sekijima.2005.73">Sekijima et al 2005</xref>].</p>
          <p>It has been demonstrated that all disease-associated TTR variants are energetically (thermodynamically and kinetically) less stable than wild-type TTR. On the other hand, suppressor variants (Thr119Met and Arg104His) are more stable than wild-type TTR. In vitro amyloidogenicity correlates very well with protein stability. However, extremely destabilized (highly amyloidogenic in vitro) TTR variants do not induce severe systemic amyloidosis because serum concentrations of these TTR variants are very low. The low serum concentration of highly destabilized TTR variants is a result of degradation by endoplasmic reticulum (ER) quality control system (ERAD) of the hepatic cells. The most pathogenic TTR variant (Leu55Pro) exhibiting the earliest disease onset is the most destabilized variant that can be secreted at levels comparable to the wild-type, barely avoiding ERAD. TTR variants that predominantly induce CNS amyloidosis are the least stable variants. The choroid plexus secretes highly destabilized TTR variants more efficiently than hepatic cells, thus, it is thought, accounting for CNS selective amyloid deposition (leptomeningeal amyloidosis) [<xref ref-type="bibr" rid="tfap.REF.hammarstr_m.2003.6656">Hammarstr&#x000f6;m et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2003.409">Sekijima et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.mitsuhashi.2005.216">Mitsuhashi et al 2005</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2005.73">Sekijima et al 2005</xref>].</p>
          <p><bold>Gene structure.</bold> Human <italic toggle="yes">TTR</italic> contains four exons and spans approximately 7 kb. All exons but exon 1 consist of fewer than 200 base pairs. Exon 1 encodes a signal peptide and the first three amino acids of the mature protein. Normal allelic variants have been described in individuals of various ethnic backgrounds (<xref ref-type="table" rid="tfap.T.ttr_variants_and_their_phenotypes">Table 5</xref>) [<xref ref-type="bibr" rid="tfap.REF.nakazato.1998.528">Nakazato 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2001.493">Saraiva 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="tfap" object-id="tfap.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> To date, more than 90 single nucleotide variants and one in-frame microdeletion have been identified in exons 2-4 in <italic toggle="yes">TTR</italic> in individuals with familial TTR amyloidosis [<xref ref-type="bibr" rid="tfap.REF.connors.2000.54">Connors et al 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2001">Benson 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2001.493">Saraiva 2001</xref>, <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al 2003</xref>, <xref ref-type="bibr" rid="tfap.REF.benson.2007.411">Benson &#x00026; Kincaid 2007</xref>]. No pathogenic variant has been described in exon 1, which encodes amino acids 1 through 3.</p>
          <p>The Val30Met pathogenic variant, found worldwide, is the most widely studied <italic toggle="yes">TTR</italic> variant and is responsible for the well-known large foci of individuals with TTR amyloid polyneuropathy in Portugal, Sweden, and Japan. Several haplotypes are associated with Val30Met in different ethnic groups, suggesting that multiple founders spontaneously occurred in each group.</p>
          <p>Val122Ile, present in 3.0%-3.9% of African Americans and more than 5.0% of the population in some areas of West Africa, is the most common amyloid-associated <italic toggle="yes">TTR</italic> variant worldwide [<xref ref-type="bibr" rid="tfap.REF.jacobson.1997.466">Jacobson et al 1997</xref>, <xref ref-type="bibr" rid="tfap.REF.yamashita.2005.127">Yamashita et al 2005</xref>].</p>
          <table-wrap id="tfap.T.ttr_variants_and_their_phenotypes" position="anchor" orientation="portrait">
            <label>Table 5. </label>
            <caption>
              <p><italic toggle="yes">TTR</italic> Variants and Their Phenotypes</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Location</th>
                  <th id="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change<break/>(Standard Nomenclature)&#x000a0;<sup>1,&#x000a0;2</sup></th>
                  <th id="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">(DNA Nucleotide Change &#x02013; Standard Nomenclature)&#x000a0;<sup>1,&#x000a0;2</sup></th>
                  <th id="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Phenotype</th>
                  <th id="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Geographic Focus</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_1" rowspan="39" valign="middle" align="left" scope="row" colspan="1">Exon 2</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Gly6Ser<break/>(p.Gly26Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.76G&#x0003e;A)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid, FEH&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Northern European origin</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Cys10Arg <break/>(p.Cys30Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.88T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, eye, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Leu12Pro<break/>(p.Leu32Pro)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.95T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM, liver</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Met13Ile<break/>(p.Met33Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.99G&#x0003e;C)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Asp18Glu<break/>(p.Asp38Glu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.114T&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">South America, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Asp18Gly<break/>(p.Asp38Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.113A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Hungary</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Asp18Asn <break/>(p.Asp38Asn)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.112G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val20lle<break/>(p.Val40Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.118G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ser23Asn <break/>(p.Ser43Asn)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.128G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Pro24Ser<break/>(p.Pro44Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.130C&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala25Ser <break/>(p.Ala45Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.133G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala25Thr<break/>(p.Ala45Thr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.133G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val28Met<break/>(p.Val48Met)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.142G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Portugal</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val30Met<break/>(p.Val50Met)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.148G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, eye, LM</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Portugal, Japan, Sweden, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val30Ala <break/>(p.Val50Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.149T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val30Leu <break/>(p.Val50Leu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.148G&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val30Gly<break/>(p.Val50Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.149T&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val32Ala <break/>(p.Val52Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.155T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Israel</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phe33Ile <break/>(p.Phe53Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.157T&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Israel</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phe33Leu <break/>(p.Phe53Leu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.157T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phe33Val <break/>(p.Phe53Val)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.157T&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK, Japan, China</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phe33Cys <break/>(p.Phe53Cys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.158T&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">CTS, heart, eye, kidney</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Arg34Thr <break/>(p.Arg54Thr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.161G&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Italy</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Arg34Gly <break/>(p.Arg54Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.160A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Lys35Asn <break/>(p.Lys55Asn)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.165G&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Lys35Thr <break/>(p.Lys55Thr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.164A&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala36Pro<break/>(p.Ala56Pro)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.166G&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Eye, CTS</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Asp38Ala<break/>(p.Asp58Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.173A&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart, lung</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Trp41Leu<break/>(p.Trp61Leu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.182G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Eye, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu42Gly<break/>(p.Glu62Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.185A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan, USA, Russia</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu42Asp <break/>(p.Glu62Asp)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.186G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phe44Ser <break/>(p.Phe64Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.191T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala45Thr<break/>(p.Ala65Thr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.193G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala45Asp <break/>(p.Ala65Asp)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.194C&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala45Ser<break/>(p.Ala65Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.193G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sweden</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly47Arg <break/>(p.Gly67Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.199G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly47Ala <break/>(p.Gly67Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.200G&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Italy, France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly47Val <break/>(p.Gly67Val)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.200G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">CTS, PN, AN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sri Lanka</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly47Glu <break/>(p.Gly67Glu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.200G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Turkey, USA, Germany</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_1" rowspan="48" valign="middle" align="left" scope="row" colspan="1">Exon 3</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Thr49Ala <break/>(p.Thr69Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.205A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France, Italy</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Thr49Ile <break/>(p.Thr69Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.206C&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan, Spain</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Thr49Pro <break/>(p.Thr69Pro)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.205A&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ser50Arg <break/>(p.Ser70Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.210T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AN, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan, France/Italy, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ser50Ile<break/>(p.Ser70Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.209G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu51Gly <break/>(p.Glu71Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.212A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ser52Pro <break/>(p.Ser72Pro)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.214T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, heart, kidney</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly53Glu<break/>(p.Gly73Glu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.218G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Basque, Sweden</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly53Ala<break/>(p.Gly73Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.218G&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu54Gly <break/>(p.Glu74Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.221A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu54Lys<break/>(p.Glu74Lys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.220G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, heart, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu54Leu<break/>(p.Glu74Leu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.220_221delGAinsCT)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Not described</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Leu55Pro<break/>(p.Leu75Pro)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.224T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, AN, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA, Taiwan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Leu55Arg <break/>(p.Leu75Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.224T&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Leu55Gln <break/>(p.Leu75Gln)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.224T&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Eye, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">His56Arg <break/>(p.His76Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.227A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly57Arg <break/>(p.Gly77Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.229G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sweden</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Leu58His <break/>(p.Leu78His)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.233T&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">CTS, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA (MD)</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Leu58Arg <break/>(p.Leu78Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.233T&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">CTS, AN, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Thr59Lys<break/>(p.Thr79Lys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.236C&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Italy, USA (Chinese)</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Thr60Ala <break/>(p.Thr80Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.238A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA (Appalachian)</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu61Lys <break/>(p.Glu81Lys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.241G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu61Gly <break/>(p.Glu81Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.242A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phe64Leu<break/>(p.Phe84Leu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.250T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, CTS, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA, Italy</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Phe64Ser<break/>(p.Phe84Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.251T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LM, PN, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Canada, UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile68Leu<break/>(p.Ile88Leu)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.262A&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Tyr69His<break/>(p.Tyr89His)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.265T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Eye, LM</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Canada, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Tyr69Ile <break/>(p.Tyr89Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.265_266delTAinsAT)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Lys70Asn<break/>(p.Lys90Asn)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.270A&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Eye, CTS, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val71Ala<break/>(p.Val91Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.272T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, Eye, CTS</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France, Spain</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile73Val <break/>(p.Ile93Val)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.277A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Bangladesh</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Asp74His<break/>(p.Asp94His)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.280G&#x0003e;C)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ser77Tyr<break/>(p.Ser97Tyr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.290C&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, kidney, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA (IL, TX), France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ser77Phe <break/>(p.Ser97Phe)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.290C&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Tyr78Phe<break/>(p.Tyr98Phe)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.293A&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, CTS, skin</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala81Thr<break/>(p.Ala101Thr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.301G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala81Val <break/>(p.Ala101Val)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.302C&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile84Ser<break/>(p.Ile104Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.311T&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA (IN), Hungary</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile84Asn <break/>(p.Ile104Asn)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.311T&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, eye</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile84Thr<break/>(p.Ile104Thr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.311T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany, UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">His88Arg<break/>(p.His108Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.323A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sweden</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu89Gln <break/>(p.Glu109Gln)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.325G&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Italy</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu89Lys <break/>(p.Glu109Lys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.325G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">His90Asn<break/>(p.His110Asn)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.328C&#x0003e;A)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany, Portugal</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">His90Asp <break/>(p.His110Asp)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.328C&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala91Ser <break/>(p.Ala111Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.331G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, CTS, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Glu92Lys <break/>(p.Gln112Lys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.334G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val94Ala <break/>(p.Val114Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.341T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN, AN, kidney</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_1" rowspan="25" valign="middle" align="left" scope="row" colspan="1">Exon 4</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ala97Gly <break/>(p.Ala117Gly)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.350C&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala97Ser <break/>(p.Ala117Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.349G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Taiwan, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Asp99Asn<break/>(p.Asp119Asn)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.355G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Denmark</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gly101Ser<break/>(p.Gly121Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.361G&#x0003e;A)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Pro102Arg<break/>(p.Pro122Arg)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.365C&#x0003e;G)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Arg103Ser<break/>(p.Arg123Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.367C&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Arg104Cys<break/>(p.Arg124Cys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.370C&#x0003e;T)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Arg104His<break/>(p.Arg124His)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.371G&#x0003e;A)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid, FEH</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan, USA (Chinese)</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile107Val <break/>(p.Ile127Val)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.379A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, CTS, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile107Met <break/>(p.Ile127Met)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.381T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Germany</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ile107Phe <break/>(p.Ile127Phe)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.379A&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">UK</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala109Thr<break/>(p.Ala129Thr)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.385G&#x0003e;A)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid, FEH</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Portugal</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala109Val<break/>(p.Ala129Val)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.385G&#x0003e;A)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid, FEH&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala109Ser <break/>(p.Ala129Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.386C&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Leu111Met <break/>(p.Leu131Met)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.391C&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Denmark</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ser112Ile <break/>(p.Ser132Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.395G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Italy</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Tyr114Cys<break/>(p.Tyr134Cys)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.401A&#x0003e;G)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, AN, eye, LM</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Tyr114His<break/>(p.Tyr134His)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.400T&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">CTS, skin</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Japan</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Tyr116Ser <break/>(p.Tyr136Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.407A&#x0003e;C)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">PN, CTS, AN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">France</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Thr119Met<break/>(p.Thr139Met)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.416C&#x0003e;T)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloid, FEH&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Portugal, USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ala120Ser <break/>(p.Ala140Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.418G&#x0003e;T)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AN, heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Afro-Caribbean</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val122Ile <break/>(p.Val142Ile)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.424G&#x0003e;A)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">delVal122<break/>(p.Val142del)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.424_426delGTC)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA, Ecuador, Spain</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Val122Ala <break/>(p.Val142Ala)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.425T&#x0003e;C</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Heart, eye, PN</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">USA</td>
                </tr>
                <tr>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Pro125Ser<break/>(p.Pro145Ser)</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(c.433C&#x0003e;T)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Non-amyloidogenic</td>
                  <td headers="hd_h_tfap.T.ttr_variants_and_their_phenotypes_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Italy</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Table derived from <xref ref-type="bibr" rid="tfap.REF.connors.2003.160">Connors et al [2003]</xref> and <xref ref-type="bibr" rid="tfap.REF.benson.2007.411">Benson &#x00026; Kincaid [2007]</xref></p>
              </fn>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn>
                <p>AN = autonomic neuropathy</p>
              </fn>
              <fn>
                <p>CTS = carpal tunnel syndrome</p>
              </fn>
              <fn>
                <p>FEH = familial euthyroid hypertyroxinemia (see <xref ref-type="sec" rid="tfap.Genetically_Related_Allelic_Disorde">Genetically Related Disorders</xref>)</p>
              </fn>
              <fn>
                <p>LM = leptomeningeal</p>
              </fn>
              <fn>
                <p>PN = peripheral neuropathy</p>
              </fn>
              <fn id="tfap.TF.5.1">
                <label>1. </label>
                <p>For the DNA nucleotide change the numbering begins at the Met initiation codon.</p>
              </fn>
              <fn id="tfap.TF.5.2">
                <label>2. </label>
                <p>For the protein amino acid change, both alternate and standard (parentheses) naming conventions are given. The alternate designations are numbered according to the beginning of the mature protein, while the standard nomenclature uses numbering beginning at the Met initiation codon and includes the 20 amino-acid signal sequence. The nucleotide naming conventions follow those of Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hgvs.org">www.hgvs.org</ext-link>). Reference sequences for the standard nomenclature are <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000371.1">NM_000371.1</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000362.1">NP_000362.1</ext-link>.</p>
              </fn>
              <fn id="tfap.TF.5.3">
                <label>3. </label>
                <p>Benign variant</p>
              </fn>
              <fn id="tfap.TF.5.4">
                <label>4. </label>
                <p>See <xref ref-type="sec" rid="tfap.Genetically_Related_Allelic_Disorde">Genetically Related Disorders</xref>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The human <italic toggle="yes">TTR</italic> cDNA encodes a 20-amino acid signal peptide plus a 127-amino acid mature protein with molecular mass 14 kd. TTR is a normal plasma protein synthesized predominantly by the liver. TTR is secreted into plasma as a tetrameric form (Mw = 55 kd) composed of four identical monomers; its plasma half-life is approximately one to two days. TTR concentration in plasma normally ranges from 20 to 40 mg/dL.</p>
          <p>TTR is considered to transport thyroxine and retinol-binding protein (RBP) coupled to vitamin A. TTR binds virtually all of serum RBP and approximately 15% of serum thyroxine. In the cerebrospinal fluid, TTR is required for transport of serum thyroxine across the blood-brain barrier.</p>
          <p>The choroid plexus is the source of the cerebrospinal fluid TTR. The TTR concentration in cerebrospinal fluid ranges from 10 &#x000b5;g/mL to 40 &#x000b5;g/mL.</p>
          <p>The other site of synthesis is the retina.</p>
          <p><bold>Abnormal gene product.</bold> It is speculated that amyloidogenic TTR variants reduce the stability of the physiologic TTR tetramer, and consequently produce a pro-amyloidogenic monomer more easily than normal TTR (see <xref ref-type="sec" rid="tfap.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>) [<xref ref-type="bibr" rid="tfap.REF.kelly.1998.101">Kelly 1998</xref>, <xref ref-type="bibr" rid="tfap.REF.rochet.2000.60">Rochet &#x00026; Lansbury 2000</xref>, <xref ref-type="bibr" rid="tfap.REF.saraiva.2002.1">Saraiva 2002</xref>, <xref ref-type="bibr" rid="tfap.REF.sekijima.2005.73">Sekijima et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="tfap.References">
        <title>References</title>
        <sec id="tfap.Published_GuidelinesConsensus_State">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="tfap.Published_GuidelinesConsensus_State.reflist0">
            <ref id="tfap.REF1">
              <mixed-citation publication-type="webpage">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">online</ext-link>. 2013. Accessed 7-13-15.</mixed-citation>
            </ref>
            <ref id="tfap.REF2">
              <mixed-citation publication-type="webpage">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">online</ext-link>. 2012. Accessed 8-11-14.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="tfap.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="tfap.Literature_Cited.reflist0">
            <ref id="tfap.REF.adams.2011.174">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lozeron</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kreib</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epelbaum</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blandin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karam</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azoulay</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adam</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaing</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuel</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients.</article-title>
                <source>Amyloid.</source>
                <volume>18</volume>
                <supplement>Suppl 1</supplement>
                <fpage>174</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21838477</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.adams.2000.1495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuel</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulon-Goeau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feray</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plante</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ducot</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichai</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metral</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bismuth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation.</article-title>
                <source>Brain</source>
                <volume>123</volume>
                <fpage>1495</fpage>
                <lpage>504</lpage>
                <pub-id pub-id-type="pmid">10869060</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.almeida.2005.641">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreira</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goncalves</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braga</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Birth of two healthy females after preimplantation genetic diagnosis for familial amyloid polyneuropathy.</article-title>
                <source>Reprod Biomed Online</source>
                <volume>10</volume>
                <fpage>641</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15949223</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ando.2003.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>New therapeutic approaches for familial amyloidotic polyneuropathy (FAP).</article-title>
                <source>Amyloid</source>
                <volume>10</volume>
                <supplement>Suppl 1</supplement>
                <fpage>55</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">14640043</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ando.2005.1057">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Araki</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Transthyretin-related familial amyloidotic polyneuropathy.</article-title>
                <source>Arch Neurol</source>
                <volume>62</volume>
                <fpage>1057</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">16009758</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.askanas.2000.544">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Askanas</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engel</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alvarez</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frangione</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghiso</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidal</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele.</article-title>
                <source>Ann Neurol</source>
                <volume>47</volume>
                <fpage>544</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10762172</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.barreiros.2010.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barreiros</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geber</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birklein</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galle</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation.</article-title>
                <source>Liver Transpl</source>
                <volume>16</volume>
                <fpage>109</fpage>
                <pub-id pub-id-type="pmid">20035516</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.beir_o.2004.2004">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beir&#x000e3;o</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lobato</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonseca</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendes</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bravo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabrita</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porto</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Kidney and anemia in familial amyloidosis type I.</article-title>
                <source>Kidney Int</source>
                <volume>66</volume>
                <fpage>2004</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15496172</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.benson.2001">
              <mixed-citation publication-type="book">Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Diseases.</italic> 8 ed. Vol 4. New York, NY: McGraw-Hill; 2001:5345-78.</mixed-citation>
            </ref>
            <ref id="tfap.REF.benson.2005.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Ostertag revisited: the inherited systemic amyloidoses without neuropathy.</article-title>
                <source>Amyloid</source>
                <volume>12</volume>
                <fpage>75</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">16011983</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.benson.2006.609">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluve-Beckerman</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeldenrust</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siesky</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodenmiller</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Showalter</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sloop</surname>
                    <given-names>KW</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides.</article-title>
                <source>Muscle Nerve</source>
                <volume>33</volume>
                <fpage>609</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">16421881</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.benson.2007.411">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kincaid</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The molecular biology and clinical features of amyloid neuropathy.</article-title>
                <source>Muscle Nerve</source>
                <volume>36</volume>
                <fpage>411</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">17554795</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.blevins.2003.1625">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blevins</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macaulay</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harder</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fladeland</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamidi Asl</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donat</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His.</article-title>
                <source>Neurology</source>
                <volume>60</volume>
                <fpage>1625</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">12771253</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.brett.1999.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brett</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persey</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Revesz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Booth</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Booth</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pepys</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan-Hughes</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis.</article-title>
                <source>Brain</source>
                <volume>122</volume>
                <fpage>183</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">10071047</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.buxbaum.2000.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buxbaum</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tagoe</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The genetics of the amyloidoses.</article-title>
                <source>Annu Rev Med</source>
                <volume>51</volume>
                <fpage>543</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">10774481</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.coelho.1994.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coelho</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sousa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lourenco</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramalheira</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected.</article-title>
                <source>J Med Genet</source>
                <volume>31</volume>
                <fpage>293</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8071954</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.connors.2003.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Connors</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokaeva</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roskens</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costello</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Tabulation of human transthyretin (TTR) variants, 2003.</article-title>
                <source>Amyloid</source>
                <volume>10</volume>
                <fpage>160</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">14640030</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.connors.2000.54">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Connors</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richardson</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theberge</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costello</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Tabulation of transthyretin (TTR) variants as of 1/1/2000.</article-title>
                <source>Amyloid</source>
                <volume>7</volume>
                <fpage>54</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">10842707</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.coutinho.2004.201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coutinho</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conceicao</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cantinho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sargento</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vagueiro</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Early detection of sympathetic myocardial denervation in patients with familial amyloid polyneuropathy type I.</article-title>
                <source>Rev Port Cardiol</source>
                <volume>23</volume>
                <fpage>201</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">15116456</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.dubrey.1997.74">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dubrey</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidoff</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergethon</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falk</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Progression of ventricular wall thickening after liver transplantation for familial amyloidosis.</article-title>
                <source>Transplantation</source>
                <volume>64</volume>
                <fpage>74</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">9233704</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ellie.2001.135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ellie</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camou</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vital</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rummens</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grateau</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delpech</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valleix</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu).</article-title>
                <source>Neurology</source>
                <volume>57</volume>
                <fpage>135</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11445644</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ericzon.2000.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ericzon</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmgren</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundgren</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suhr</surname>
                    <given-names>OB</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders and the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Ume&#x000e5; Sweden, June 1999.</article-title>
                <source>Amyloid</source>
                <volume>7</volume>
                <fpage>145</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10842720</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ferlini.1996.10">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferlini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uncini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>el-Chami</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Repetto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Littardi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campoleoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vezzoni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patrosso</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Homozygosity and heterozygosity for the transthyretin Leu64 mutation: clinical, biochemical and molecular findings.</article-title>
                <source>Clin Genet.</source>
                <volume>49</volume>
                <fpage>10</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">8721565</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.goto.2006.2512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohshima</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoneyama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nanjo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asonuma</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inomata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation.</article-title>
                <source>Am J Transplant</source>
                <volume>6</volume>
                <fpage>2512</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16889603</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.haagsma.2004.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haagsma</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bybee</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hazenberg</surname>
                    <given-names>BP</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families.</article-title>
                <source>Amyloid</source>
                <volume>11</volume>
                <fpage>44</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15185498</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.hammarstr_m.2001.2459">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hammarstr&#x000f6;m</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Trans-suppression of misfolding in an amyloid disease.</article-title>
                <source>Science</source>
                <volume>293</volume>
                <fpage>2459</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">11577236</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.hammarstr_m.2003.6656">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hammarstr&#x000f6;m</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiseman</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costello</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garzuly</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?</article-title>
                <source>Biochemistry</source>
                <volume>42</volume>
                <fpage>6656</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">12779320</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.hattori.2003.229">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koyama</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy.</article-title>
                <source>Amyloid</source>
                <volume>10</volume>
                <fpage>229</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">14986482</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.hellman.2008.181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hellman</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alarcon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundgren</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suhr</surname>
                    <given-names>OB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaiti-Pelli&#x000e9;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plant&#x000e9;-Bordeneuve</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population.</article-title>
                <source>Amyloid</source>
                <volume>15</volume>
                <fpage>181</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18925456</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.herlenius.2004.64">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herlenius</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilczek</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ericzon</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.</article-title>
                <source>Transplantation</source>
                <volume>77</volume>
                <fpage>64</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">14724437</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.holmgren.1997.178">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmgren</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wikstrom</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP) (TTR met30).</article-title>
                <source>Amyloid</source>
                <volume>4</volume>
                <fpage>178</fpage>
                <lpage>80</lpage>
              </element-citation>
            </ref>
            <ref id="tfap.REF.holmgren.1994.351">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmgren</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asplund</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nylander</surname>
                    <given-names>PO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teixeira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>PP</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.</article-title>
                <source>J Med Genet</source>
                <volume>31</volume>
                <fpage>351</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">8064809</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.h_rnsten.2004.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000f6;rnsten</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiklund</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olofsson</surname>
                    <given-names>BO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suhr</surname>
                    <given-names>OB</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients.</article-title>
                <source>Transplantation</source>
                <volume>78</volume>
                <fpage>112</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15257048</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.hund.2001.431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hund</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linke</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grau</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.</article-title>
                <source>Neurology</source>
                <volume>56</volume>
                <fpage>431</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11261421</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ikeda.2004.1107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Cardiac amyloidosis: heterogenous pathogenic backgrounds.</article-title>
                <source>Intern Med</source>
                <volume>43</volume>
                <fpage>1107</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">15645642</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ikeda.1987.315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanyu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hongo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshioka</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oguchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukagoshi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokota</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients.</article-title>
                <source>Brain</source>
                <volume>110</volume>
                <fpage>315</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">3032328</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ikeda.2002.1001">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobue</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity.</article-title>
                <source>Neurology</source>
                <volume>58</volume>
                <fpage>1001</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11940682</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ikeda.1983.1055">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukahara</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Histochemical study of rectal aminergic nerves in type I familial amyloid polyneuropathy.</article-title>
                <source>Neurology</source>
                <volume>33</volume>
                <fpage>1055</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">6683801</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ikeda.2003.547">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashikura</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Liver transplantation as treatment for neurological disorders.</article-title>
                <source>Expert Rev Neurother</source>
                <volume>3</volume>
                <fpage>547</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">19810938</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ikeda.1997.618">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsunami</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashikura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikegami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawasaki</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation.</article-title>
                <source>Ann Intern Med</source>
                <volume>127</volume>
                <fpage>618</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">9341060</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ikeda.1982.1364">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makishita</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagata</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1982</year>
                <article-title>Gastrointestinal amyloid deposition in familial amyloid polyneuropathy.</article-title>
                <source>Neurology</source>
                <volume>32</volume>
                <fpage>1364</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">6890642</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.jacob.2007.127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacob</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>WD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zucker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Cruz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seshan</surname>
                    <given-names>SV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crow</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Highsmith</surname>
                    <given-names>WE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Homozygous transthyretin mutation in an African American male.</article-title>
                <source>J Mol Diagn</source>
                <volume>9</volume>
                <fpage>127</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">17251346</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.jacobson.1990.127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacobson</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorevic</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buxbaum</surname>
                    <given-names>JN</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology.</article-title>
                <source>Am J Hum Genet</source>
                <volume>47</volume>
                <issue>1</issue>
                <fpage>127</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">2349941</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.jacobson.1997.466">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacobson</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastore</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaghoubian</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kane</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buck</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buxbaum</surname>
                    <given-names>JN</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.</article-title>
                <source>N Engl J Med</source>
                <volume>336</volume>
                <fpage>466</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">9017939</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.jin.2004.1463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Date</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tominaga</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoyama</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>75</volume>
                <fpage>1463</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15377697</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.juneblad.2004.208">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Juneblad</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naslund</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olofsson</surname>
                    <given-names>BO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suhr</surname>
                    <given-names>OB</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Outcome of exercise electrocardiography in familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation.</article-title>
                <source>Amyloid</source>
                <volume>11</volume>
                <fpage>208</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">15523924</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.kawaji.2004.257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kawaji</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanihara</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy.</article-title>
                <source>Amyloid</source>
                <volume>11</volume>
                <fpage>257</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15678760</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.kelly.1998.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The alternative conformations of amyloidogenic proteins and their multi- step assembly pathways.</article-title>
                <source>Curr Opin Struct Biol</source>
                <volume>8</volume>
                <fpage>101</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9519302</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.koike.2002.1771">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koike</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobue</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Study Group for Hereditary Neuropathy in Japan. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form.</article-title>
                <source>Arch Neurol</source>
                <volume>59</volume>
                <fpage>1771</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12433265</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.koike.2004.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koike</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugiura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iijima</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mori</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mukai</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobue</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy.</article-title>
                <source>Neurology</source>
                <volume>63</volume>
                <fpage>129</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">15249622</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.llad_.2010.1386">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Llad&#x000f3;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baliellas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casasnovas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fabregat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellote</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torras</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiol</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rafecas</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation.</article-title>
                <source>Liver Transpl</source>
                <volume>16</volume>
                <fpage>1386</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">21117248</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.lobato.2004.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lobato</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beir&#x000e3;o</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonseca</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Queiros</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocha</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarmento</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sousa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sequeiros</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors.</article-title>
                <source>Amyloid</source>
                <volume>11</volume>
                <fpage>27</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">15185496</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.longo_alves.1997.662">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Longo Alves</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hays</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJM</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin.</article-title>
                <source>Eur J Biochem</source>
                <volume>249</volume>
                <fpage>662</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9395311</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.love.2010.1864">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Love</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahon</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levins</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whitehead</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Querbes</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorkin</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cantley</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Racie</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frank-Kamenetsky</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yip</surname>
                    <given-names>KN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alvarez</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sah</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Fougerolles</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgerald</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koteliansky</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akinc</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Lipid-like materials for low-dose, in vivo gene silencing.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>107</volume>
                <fpage>1864</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20080679</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.mascalchi.1999.1498">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mascalchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirini</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Errico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferlini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lolli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plasmati</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tessa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villari</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassinari</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Transthyretin amyloidosis and superficial siderosis of the CNS.</article-title>
                <source>Neurology</source>
                <volume>53</volume>
                <fpage>1498</fpage>
                <lpage>503</lpage>
                <pub-id pub-id-type="pmid">10534258</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.miller.2004.545">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.</article-title>
                <source>Lab Invest</source>
                <volume>84</volume>
                <fpage>545</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">14968122</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.misu.2000.451">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Misu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobue</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Anticipation in early - but not late-onset familial amyloid polyneuropathy (TTR Met30) in Japan.</article-title>
                <source>Neurology</source>
                <volume>55</volume>
                <fpage>451</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">10932290</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.misu.1999.1951">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Misu</surname><given-names>K</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>N</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>M</given-names></name></person-group>Ikeda Si, Ando Y, Nakazato M, Takei Yi Y, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G<year>1999</year><article-title>Late-onset familial amyloid polyneuropathy type I (transthyretin Met30- associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features.</article-title><source>Brain</source><volume>122</volume><fpage>1951</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10506096</pub-id></mixed-citation>
            </ref>
            <ref id="tfap.REF.mitsuhashi.2005.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mitsuhashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Washimi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis.</article-title>
                <source>Amyloid</source>
                <volume>12</volume>
                <fpage>216</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">16399646</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.mitsuhashi.2004.265">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mitsuhashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>MRI analysis on a patient with the V30M mutation is characteristic of leptomeningeal amyloid.</article-title>
                <source>Amyloid</source>
                <volume>11</volume>
                <fpage>265</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15678762</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.mochizuki.2001.105">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mochizuki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamakura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motoyoshi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Nodular cutaneous amyloidosis and carpal tunnel syndrome due to the amyloidogenic transthyretin His 114 variant.</article-title>
                <source>Amyloid</source>
                <volume>8</volume>
                <fpage>105</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">11409031</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.munarqu_s.2001.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Munar-Qu&#x000e9;s</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes Dominguez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viader-Farre</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreira</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Two Spanish sibs with familial amyloidotic polyneuropathy homozygous for the V30M-TTR gene.</article-title>
                <source>Amyloid</source>
                <volume>8</volume>
                <fpage>121</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">11409034</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.munarqu_s.1999.629">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Munar-Qu&#x000e9;s</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedrosa</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coelho</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gusmao</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seruca</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amorim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sequeiros</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Two pairs of proven monozygotic twins discordant for familial amyloid neuropathy (FAP) TTR-Met30.</article-title>
                <source>J Med Genet</source>
                <volume>36</volume>
                <fpage>629</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">10465115</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.nakazato.1998.528">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Genotype-phenotype relationship in familial amyloid polyneuropathy.</article-title>
                <source>Neurol Med (Tokyo)</source>
                <volume>48</volume>
                <fpage>528</fpage>
                <lpage>34</lpage>
              </element-citation>
            </ref>
            <ref id="tfap.REF.ng.2005.1425">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connors</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidoff</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falk</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.</article-title>
                <source>Arch Intern Med</source>
                <volume>165</volume>
                <fpage>1425</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15983293</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.nichols.1991.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liepnieks</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snyder</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>1991</year>
                <article-title>Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE-122).</article-title>
                <source>J Lab Clin Med</source>
                <volume>117</volume>
                <fpage>175</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">2002274</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.obayashi.2011.449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Obayashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tasaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shono</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jono</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohshima</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohya</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asonuma</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inomata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Amyloid neuropathy in a younger domino liver transplanted recipient.</article-title>
                <source>Muscle Nerve</source>
                <volume>43</volume>
                <fpage>449</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">21319169</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.perfetto.2011.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perfetto</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergesio</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany?</article-title>
                <source>J Cardiovasc Med (Hagerstown)</source>
                <volume>12</volume>
                <fpage>450</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">21540676</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.petersen.1997.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Petersen</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goren</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richardson</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tresser</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gali</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambetti</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Transthyretin amyloidosis: a new mutation associated with dementia.</article-title>
                <source>Ann Neurol</source>
                <volume>41</volume>
                <fpage>307</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">9066351</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.plant_bordeneuve.1998.708">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plant&#x000e9;-Bordeneuve</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misrahi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy.</article-title>
                <source>Neurology</source>
                <volume>51</volume>
                <fpage>708</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">9748014</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.plant_bordeneuve.2003.e120">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plant&#x000e9;-Bordeneuve</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carayol</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clerget-Darpoux</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misrahi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bona&#x000ef;ti-Pelli&#x000e9;</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.</article-title>
                <source>J Med Genet</source>
                <volume>40</volume>
                <fpage>e120</fpage>
                <pub-id pub-id-type="pmid">14627687</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.plant_bordeneuve.2007.693">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plant&#x000e9;-Bordeneuve</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaros</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP).</article-title>
                <source>Neurology</source>
                <volume>69</volume>
                <fpage>693</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17698792</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.rochet.2000.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rochet</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lansbury</surname>
                    <given-names>PT</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Amyloid fibrillogenesis: themes and variations.</article-title>
                <source>Curr Opin Struct Biol</source>
                <volume>10</volume>
                <fpage>60</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10679462</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.saraiva.2001.493">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Transthyretin mutations in hyperthyroxinemia and amyloid diseases.</article-title>
                <source>Hum Mutat</source>
                <volume>17</volume>
                <fpage>493</fpage>
                <lpage>503</lpage>
                <pub-id pub-id-type="pmid">11385707</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.saraiva.2002.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.</article-title>
                <source>Expert Rev Mol Med</source>
                <volume>4</volume>
                <fpage>1</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">14987380</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sebasti_o.2001.733">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sebasti&#x000e3;o</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamzin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damas</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.</article-title>
                <source>J Mol Biol</source>
                <volume>306</volume>
                <fpage>733</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">11243784</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sekijima.2006.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dendle</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.</article-title>
                <source>Amyloid</source>
                <volume>13</volume>
                <fpage>236</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">17107884</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sekijima.2003.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammarstrom</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwata</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.</article-title>
                <source>Lab Invest</source>
                <volume>83</volume>
                <fpage>409</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">12649341</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sekijima.2008.3219">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.</article-title>
                <source>Curr Pharm Des</source>
                <volume>14</volume>
                <fpage>3219</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">19075702</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sekijima.2001.257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kametani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maruyama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Serum transthyretin monomer in patients with familial amyloid polyneuropathy.</article-title>
                <source>Amyloid</source>
                <volume>8</volume>
                <fpage>257</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">11791618</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sekijima.2011.1785">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchiyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tojo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imaeda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoshii</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly.</article-title>
                <source>Hum Pathol</source>
                <volume>42</volume>
                <fpage>1785</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">21733562</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sekijima.2005.73">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiseman</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matteson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammarstrom</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawkar</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balch</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The biological and chemical basis for tissue-selective amyloid disease.</article-title>
                <source>Cell</source>
                <volume>121</volume>
                <fpage>73</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">15820680</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.soares.1999.480">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Soares</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buxbaum</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sirugo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coelho</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sousa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kastner</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions.</article-title>
                <source>Hum Genet</source>
                <volume>104</volume>
                <fpage>480</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10453736</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.soares.2005.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Soares</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coelho</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sousa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batalov</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Concei&#x000e7;&#x000e3;o</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sales-Lu&#x000ed;s</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ritchie</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nievergelt</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schork</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buxbaum</surname>
                    <given-names>JN</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease.</article-title>
                <source>Hum Mol Genet</source>
                <volume>14</volume>
                <fpage>543</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">15649951</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.sobue.2003.32">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sobue</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koike</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inukai</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan.</article-title>
                <source>Amyloid</source>
                <volume>10</volume>
                <supplement>Suppl 1</supplement>
                <fpage>32</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14640040</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.stangou.2004.615">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stangou</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>PN</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Liver transplantation in transthyretin-related familial amyloid polyneuropathy.</article-title>
                <source>Curr Opin Neurol</source>
                <volume>17</volume>
                <fpage>615</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">15367866</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.stangou.1998.229">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stangou</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heaton</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rela</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monaghan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nihoyannopoulos</surname>
                    <given-names>P, O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grady</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pepys</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. implications for amyloid fibrillogenesis.</article-title>
                <source>Transplantation</source>
                <volume>66</volume>
                <fpage>229</fpage>
                <pub-id pub-id-type="pmid">9701270</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.stangou.2005.2356">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stangou</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heaton</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>PN</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation.</article-title>
                <source>N Engl J Med</source>
                <volume>352</volume>
                <fpage>2356</fpage>
                <pub-id pub-id-type="pmid">15930432</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.tachibana.1999.282">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tachibana</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taketomi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakazato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>YF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masuda</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy.</article-title>
                <source>Amyloid</source>
                <volume>6</volume>
                <fpage>282</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10611950</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.takei.1999.592">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashikura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikegami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawasaki</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients.</article-title>
                <source>Ann Intern Med</source>
                <volume>131</volume>
                <fpage>592</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10523220</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.tojo.2006.441">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tojo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.</article-title>
                <source>Neurosci Res.</source>
                <year>2006</year>
                <volume>56</volume>
                <fpage>441</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17028027</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.tojo.2008.796">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tojo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sekijima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Machida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuchiya</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy.</article-title>
                <source>Muscle Nerve.</source>
                <year>2008</year>
                <volume>37</volume>
                <fpage>796</fpage>
                <lpage>803</lpage>
                <pub-id pub-id-type="pmid">18506713</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.uemichi.1999.1152">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Uemichi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitti</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeppen</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donat</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64.</article-title>
                <source>Arch Neurol</source>
                <volume>56</volume>
                <fpage>1152</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10488818</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.vita.2005.259">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vita</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzeo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Leo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferlini</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>15</volume>
                <fpage>259</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15725588</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.vital.2004.232">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vital</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vital</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouillot-Eimer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brechenmacher</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lagueny</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies.</article-title>
                <source>J Peripher Nerv Syst</source>
                <volume>9</volume>
                <fpage>232</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">15574136</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.westermark.2003.48">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Westermark</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergstrom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solomon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sletten</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.</article-title>
                <source>Amyloid</source>
                <volume>10</volume>
                <supplement>Suppl 1</supplement>
                <fpage>48</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">14640042</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.yamamoto.1998.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanyu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy.</article-title>
                <source>J Med Genet</source>
                <volume>35</volume>
                <fpage>23</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">9475090</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.yamashita.2005.127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asl</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population.</article-title>
                <source>Amyloid</source>
                <volume>12</volume>
                <fpage>127</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">16011990</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.yazaki.2002.263">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connors</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eagle</surname>
                    <given-names>RC</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Leff</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Transthyretin amyloidosis associated with a novel variant (Trp41Leu) presenting with vitreous opacities.</article-title>
                <source>Amyloid</source>
                <volume>9</volume>
                <fpage>263</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12557756</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.yazak.2000">
              <mixed-citation publication-type="other">Yazak M, Take YI, Katoh M, Ikeda SI (2000) Postmortem findings in two familial amyloidosis patients with transthyretin variant Asp38Ala. Amyloid. 7:270-7</mixed-citation>
            </ref>
            <ref id="tfap.REF.yazaki.2000.702">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higashikata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koyama</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higuchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harihara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baba</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kametani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>274</volume>
                <fpage>702</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10924339</pub-id>
              </element-citation>
            </ref>
            <ref id="tfap.REF.yoshinaga.2004.56">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yoshinaga</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katayanagi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30Met transthyretin gene.</article-title>
                <source>Amyloid</source>
                <volume>11</volume>
                <fpage>56</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">15185500</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="tfap.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="tfap.Suggested_Reading.reflist0">
            <ref id="tfap.REF.plant_bordeneuve.2011.1086">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plant&#x000e9;-Bordeneuve</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Familial amyloid polyneuropathy.</article-title>
                <source>Lancet Neurol</source>
                <volume>10</volume>
                <fpage>1086</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">22094129</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="tfap.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="tfap.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 January 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 September 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 March 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>2 March 2005 (cd) Revision: mutation scanning and sequencing of select exons no longer clinically available</p>
            </list-item>
            <list-item>
              <p>5 March 2004 (ky) Revision: molecular genetic testing</p>
            </list-item>
            <list-item>
              <p>9 January 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>5 November 2001 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>25 June 2001 (ky) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
